 
CONFIDENTIAL  
This material is the proper ty of the UTSW Simmons Cancer Center . Do not disclose or use except as authorized in writing by the study sponsor.  
 
Phase II study of e nzalutamide  (MDV3100)  and gonadotropin -releasing hormone (GnRH) 
agonist before, during, and after radiation therapy in treatment of patients with high -risk 
localized prostate cancer  
 
 
[STUDY_ID_REMOVED]  
 
Date Approved: 12/29/ 2016 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONFIDENTIAL  
This material is the proper ty of the UTSW Simmons Cancer Center . Do not disclose or use except as authorized in writing by the study sponsor.  
 
 
PROTOCOL NUMBER  
Phase I I study of e nzalutamide  (MDV3100)  and gonadotropin -releasing hormone 
(GnRH) agonist before, during, and after radiation therapy in treatment of patients 
with high -risk localized prostate cancer  
 
Principal In vestigator :  Kevin Courtney, MD, PhD  
   Assistant Professor  
   UT Southwestern Medical Center  
   Division of Hematology/Oncology  
   5323 Harry Hines Boulevard  
   Dallas, TX  75390 -8852  
   Telephone: 214/648 -4180 (academic office)  
   Telephone: 214/648 -1948 (direct extension)  
    Fax: 214/648 -1955  
 
Co-Investigators:   Yull Arriaga, MD  
    Raquibul Hannan, MD, PhD    
     
    Yi Yin, MD, PhD  
    Michael Folkert, MD  
    Aaron Laine, MD  
    Neil Desai, MD  
 
Biostatistician :   Chul Ahn, PhD  
    UT Southwestern Med ical Center  
    5323 Harry Hines Boulevard, Dallas, TX  75390 -9066  
    (Phone ) 214-648-9148  
    Email  chul.ahn@utsouthwestern.edu  
 
Study Drug:    Enzalutamide (Xtandi)  
 
IND Number:    N/A. 
 
IND Holder Name:   N/A. 
 
Funding Source :  Astellas Pharma U.S., Inc.;  Medivation, Inc  
 
Initial version:    28 Aug 2013  
 
Amended:                       27 Sep 2013  
               26 Dec 2014  
    10 Apr  2015  
    29 Jun 2015   
               18 Feb 2016  
    06Jun 2016  
    29 Dec 2016  
    UT Southwestern Medical Center at Dallas  
Harold C. Simmons Cancer Center  
Attn: Clinical Research Office  
5323 Harry Hines Blvd. MC 9179  
Dallas, Texas 75390 -9179  
 
 
CONFIDENTIAL  
This material is the proper ty of the UTSW Simmons Cancer Center . Do not disclose or use except as authorized in writing by the study sponsor.  
 
 
 
 
Signature Page  
 
 
The signature below constitutes the approval of this protocol and the attachments, and provides the 
necessary assura nces that this trial will be conducted according to all stipulations of the protocol, including 
all statements regarding confidentiality, and according to local legal and regulatory requirements and 
applicable U.S. federal regulations and ICH guidelines.  
 
 
 
Principal Investigator (PI) Name :_____________________________  
 
 
 
PI Signature: __________ __________ _________  
 
 
 
Date:____________________  
 
________________________________________________________________________  
i TABLE OF CONTENTS  
LIST OF ABBREVIATIONS ................................ ................................ ................................ .............  1 
STUDY SCHEMA  ................................ ................................ ................................ ............................  3 
STUDY SUMMARY  ................................ ................................ ................................ .........................  3 
1.0 BACKGROUND AND RATIONALE  ................................ ................................ ......................  5 
1.1 Disease Background ................................ ................................ ................................ ........  5 
1.2 Study Agent(s) Background and Associated Known Toxicities  ................................ ....... 5 
1.3 Other Agents  ................................ ................................ ................................ ..................  10 
1.4 Rationale  ................................ ................................ ................................ ........................  10 
1.5 Correlative Studies  ................................ ................................ ................................ ........  12 
2.0 STUDY OBJECTIVES  ................................ ................................ ................................ .........  12 
2.1 Primary Objectives  ................................ ................................ ................................ .........  12 
2.2 Secondary Objectives  ................................ ................................ ................................ .... 12 
2.3 Exploratory Objectives  ................................ ................................ ................................ ... 13 
2.4 Endpoints  ................................ ................................ ................................ .......................  13 
3.0 PATIENT ELIGIBILITY  ................................ ................................ ................................ ........  13 
3.1 Inclusion Criteria  ................................ ................................ ................................ ............  13 
3.2 Exclusion Criteria  ................................ ................................ ................................ ...........  15 
4.0 TREATMENT PLAN  ................................ ................................ ................................ ............  16 
4.1 Treatment Dosage and Administration  ................................ ................................ ..........  16 
4.2 Toxicities and Dosing Delays/Dose Modifi cations  ................................ .........................  17 
4.3 Concomitant Medications/Treatments  ................................ ................................ ...........  18 
4.4 Other Modalities or Procedures  ................................ ................................ .....................  19 
4.5 Duration of Therapy  ................................ ................................ ................................ ....... 25 
4.6 Duration of Follow Up  ................................ ................................ ................................ .... 25 
________________________________________________________________________  
ii 4.7 Removal of Patients from Protocol Therapy  ................................ ................................ .. 25 
4.8 Patient Replacement  ................................ ................................ ................................ ..... 25 
5.0 STUDY PROCEDURES  ................................ ................................ ................................ ....... 25 
5.1 Scree ning/Baseline Procedures  ................................ ................................ ....................  25 
5.2 Procedures During Treatment  ................................ ................................ .......................  27 
5.3 Follow -up Procedures  ................................ ................................ ................................ .... 27 
5.4 Time and Events Table  ................................ ................................ ................................ .. 28 
5.5 Removal of Subjects from Study  ................................ ................................ ...................  28 
6.0 MEASUREMENT OF EFFEC T ................................ ................................ ............................  29 
6.1 Antitumor Effect - Solid Tumors  ................................ ................................ ......................  29 
6.2 Safety/T olerability  ................................ ................................ ................................ ..........  30 
7.0 ADVERSE EVENTS  ................................ ................................ ................................ .............  31 
7.1 Experimental Therapy ................................ ................................ ................................ .... 31 
7.2 Adverse Event Monitoring  ................................ ................................ .............................  32 
7.3 Definitions  ................................ ................................ ................................ ......................  33 
7.4 Steps to Determine If an Adverse Event Requires Expedited Reporting  ......................  36 
7.5 Reporting Requirements for Adverse Events  ................................ ................................  36 
7.6 Unblinding Procedures  ................................ ................................ ................................ .. 37 
7.7 Stopping Rules  ................................ ................................ ................................ ..............  37 
8.0 DRUG INFORMATION  ................................ ................................ ................................ ........  37 
8.1 Enzalutamide  ................................ ................................ ................................ .................  37 
9.0 CORRELATIVES/SPECIAL STUDIES  ................................ ................................ ................  38 
9.1 Sample Collection Guidelines  ................................ ................................ ........................  38 
9.2 Assay Methodology  ................................ ................................ ................................ ....... 39 
9.3 Specimen Banking  ................................ ................................ ................................ .........  39 
10.0 STATISTICAL CONSIDERATIONS  ................................ ................................ ..................  40 
________________________________________________________________________  
iii 10.1 Study Design/Study Endpoints  ................................ ................................ ......................  40 
10.2 Sample Size and Accrual  ................................ ................................ ..............................  40 
10.3 Data Analyses Plans ................................ ................................ ................................ ...... 41 
11.0 STUDY MANAGEMENT  ................................ ................................ ................................ .... 41 
11.1 Conflict of Interest  ................................ ................................ ................................ ..........  41 
11.2 Institutional Review Board (IRB) Approval and Consent  ................................ ...............  41 
11.3 Data Management and Monitoring/Auditing  ................................ ................................ .. 42 
11.4 Adherence to the Protocol  ................................ ................................ .............................  42 
11.5 Amendments to the Protocol  ................................ ................................ .........................  43 
11.6 Record Retention  ................................ ................................ ................................ ...........  43 
11.7 Obligations of Investigators  ................................ ................................ ...........................  43 
12.0 REFERENCES  ................................ ................................ ................................ ...................  43 
13.0 APPENDICES  ................................ ................................ ................................ ....................  45 
________________________________________________________________________  
1 LIST OF ABBREVIATIONS  
 
Examples Include:  
  
3D-CRT Three Dimensional Conformal Radiation Therapy  
ADC  Apparent Diffusion  Coefficient  
ADT Androgen Deprivation Therapy  
AE Adverse Event  
ALT Alanine Aminotransferase  
ANC Absolute Neutrophil  Count  
AR Androgen Receptor  
AST Aspartate Aminotransferase  
AUC  Area Under Curve  
BUN  Blood Urea Nitrogen  
CaP Prostatic Adenocarcinoma  
CBC  Complete Blood Count  
CLIA  Clinical Laboratory Improvement Amendments  
CMP  Comprehensive Metabolic Panel  
CRPC Castrate -Resistant Prostate Cancer  
CT Computed Tomography  
CTV Clinical Target Volume  
CTC Common Toxicity Criteria  
CTCAE  Common T oxicity  Criteria for Adverse Events  
DHEA Dehydroepiandrosterone  
DHT Dihydrotestosterone  
DSMB  Data and Safety Monitoring Board  
EBRT  External Beam Radiation Therapy  
  
ECOG  Eastern Cooperative Oncology Group  
eGFR  Estimated Glomerular Filtration Rate  
EORTC  European Organization for Research and Treatment of Cancer  
FDA Federal Drug Administration  
GnRH  Gonadotropin Releasing Hormone  
GTV Gross Tumor Volume  
H&P History & Physical Exam  
HRPP  Human Research Protections Program  
IC50  Inhibitory Concentration 50%  
IMRT  Intensity -Modulated Radiation Therapy  
IRB Institutional Review Board  
IV (or iv)  Intravenously  
kV Kilovoltage  
LDH Lactate Dehydrogenase  
MG (or mg)  Milligram  
________________________________________________________________________  
2 ML (or mL)  Milliliter  
MRI Magnetic Resonance Imaging  
MV Megavoltage  
NCCN  National Com prehensive Cancer Network  
NCI National Cancer Institute  
NG (or ng)  Nanogram  
PK Pharmacokinetics  
PSA Prostate Specific Antigen  
PD Progressive Disease  
PFS Progression Free Survival  
p.o. peros/by mouth/orally  
PR Partial Response  
PTV Planning Target V olume  
qRT-PCR  Quantitative Reverse Transcription Polymerase Chain Reaction  
RTOG - 
ASTRO  Radiation Therapy Oncology Group – American Society for Therapeutic 
Radiology and Oncology  
SAE Serious Adverse Event  
SD Stable Disease  
SGOT  Serum Glutamic Oxaloacet ic Transaminase  
SPGT  Serum Glutamic Pyruvic Transaminase  
T1/2 (or t1/2)  Half-life 
TRUS  Transrectal Ultrasound  
WBC  White Blood Cells  
  
  
 
  
________________________________________________________________________  
3 STUDY SCHEMA  
 
 
STUDY SUMMARY  
Title Phase I I pilot  study of enzalutamide (MDV3100) and gonadotropin -
releasing  hormone (GnRH) agonist before, during, and after radiation 
therapy in treatment of patients with high -risk localized prostate cancer  
Short Title  Phase II trial of radiation with enzalutamide  (MDV3100)  and androgen 
deprivation  
Protocol Number  The standar d protocol number used to identify this study  
Phase  2 
Methodology  Open label  
Study Duration  5 years  
Study Center(s)  Single -center  
Objectives  This is a single institution phase II trial studying the safety and efficacy of 
combined enzalutamide and GnR H agonist therapy administered with 
EBRT for high -risk and locally advanced prostate cancer.  
Number of Subjects  7 
 
________________________________________________________________________  
4 Diagnosis and Main 
Inclusion Criteria  - Patients must be candidates for long -term androgen 
deprivation in combination with EBRT for the treat ment of 
high-risk or locally -advanced prostate cancer by the following 
criteria:  
o High risk disease: T3a or Gleason 8 -10 or serum 
PSA > 20 ng/mL  
 Gleason 7 also allowed if > 50% of cores 
positive for cancer or PSA velocity > 2 
ng/mL/year in preceding 12 mont hs 
o Locally advanced (very high risk) disease: T3b -T4 
-   
- Patients may have radiographic evidence of metastasis in 
regional lymph nodes (N1 disease as defined by the National 
Comprehensive Cancer Network Prostate Cancer Guideline 
Verson 3.2012) at the discret ion of the treating physicians, if 
regional lymph nodes can be included in the planned 
radiation field.  
 
Study Product (s), Dose, 
Route, Regimen  Enzalutamide  (MDV3100)  (Xtandi), 4 x 40 mg capsules  (160 mg total) by 
mouth daily  
Duration of administration  6 months  
Reference therapy  N/A 
Statistical Methodology  Descriptive statistics will be used in the analysis of safety and tolerability 
and the outlined imaging and biological correlates.  
 
  
________________________________________________________________________  
5  
1.0 BACKGROUND AND RATIONALE  
1.1 Disease Background  
Androgens fuel the gr owth of prostate cancer cells. Interfering with androgen signaling 
impairs prostate cancer growth. External beam radiation therapy (EBRT) employs x -rays 
to kill tumor cells  and is an effective treatment for localized prostate cancer. Previous 
clinical tria ls have demonstrated that combining EBRT with inhibitors of androgen 
signaling improves overall survival in patients with high -risk and locally -advanced 
prostate cancer.1-9 D’Amico and colleagues reported that 6 months of combined 
androgen suppression therapy by administration of a GnRH agonist and an anti -
androgen before, during, and after EBRT improved survival compared to EBRT alone in 
patients with intermediate -risk or high -risk prostate cancer.4 RTOG 9202 was a 
randomized study of 1521 patients treated with radiation therapy plus 4 months of the 
GnRH agonist goserelin with  the anti -androgen flutamide before and during radiation 
therapy, followed by 0 vs 24 months of goserelin.5 The study showed an improvement in 
disease free surviva l at 10 years. Overall survival showed no statistically significant 
difference between the two arms, but subgroup analysis showed an overall survival 
benefit for patients with prostatic adenocarcinoma of Gleason score 8 -10.5 In the phase 
III randomized trial EORTC 22961 , Bolla and colleagues subsequently reported that 3 
years of androgen suppression therapy (comprised of 6 months of combined GnRH 
agonist and androge n receptor antagonist treatment followed by 30 months of GnRH 
agonist therapy) before, during, and after EBRT lead to improved overall survival 
compared to 6 months of combined androgen suppression therapy plus EBRT in patients 
with high -risk prostate canc er.2 Taken together, t hese data provide category 1 evidence 
for treatment of high -risk and locally advanced prostate cancer with EBRT plus long -term 
neoadjuvant / co ncomitant / adjuvant androgen suppression therapy for 2 -3 years as a 
standard of care (www.nccn.org). However, a substantial proportion of these patients will 
develop metastatic prostate cancer and die as a result of their metastatic disease. We 
propose th at enzalutamide plus GnRH agonist treatment in combination with EBRT 
should be safe and well tolerated for the treatment of prostate canc er. We propose to 
carry out a pilot phase II study to assess the safety and tolerability of this combination, 
along wit h imaging and biologic correlates to assess response to enzalutamide plus 
GnRH treatment prior to initiation of EBRT. We hypothesize that enzalutamide plus 
GnRH agonist combined with EBRT may improve survival compared to standard 
treatment with GnRH agonis t plus first -generation anti -androgens combined with EBRT.  
1.2 Study Agent(s) Background and Associated Known Toxicities  
Enzalutamide (MDV3100, Xtandi) is an androgen receptor inhibitor. In August 2012, 
enzalutamide received US FDA approval for the treatment of patients with metastatic 
castration -resistant prostate cancer who have previously received docetaxel. The 
approved dose of enzalutamide is 160 mg (four 40 mg capsules) by mouth once daily.  
 
Although the primary endpoint of this study is to assess the sa fety and tolerability of 
enzalutamide plus GnRH agonist combined with EBRT, there is no reason a priori to 
believe that this combination of therapy will increase the known potential risks associated 
with enzalutamide. There may be unexpected risks from thi s combination, and this 
possibility will be evaluated in the clinical study.  
 
We believe that this study meets criteria for exemption from application for an 
Investigational New Drug (IND) based on the following criteria as enumerated in the 
Code of Feder al Regulations (CFR 312.2) and copied directly below:  
 
________________________________________________________________________  
6 “Exemptions. (1) The clinical investigation of a drug product that is lawfully marketed in 
the United States is exempt from the requirements of this part if all the following apply:  
 
(i) The investigat ion is not intended to be reported to FDA as a well -controlled study in 
support of a new indication for use nor intended to be used to support any other 
significant change in the labeling for the drug;  
 
(ii) If the drug that is undergoing investigation is lawfully marketed as a prescription drug 
product, the investigation is not intended to support a significant change in the advertising 
for the product;  
 
(iii) The investigation does not involve a route of administration or dosage level or use in 
a patient population or other factor that significantly increases the risks (or decreases the 
acceptability of the risks) associated with the use of the drug product;  
 
(iv) The investigation is conducted in compliance with the requirements for institutional 
review s et forth in part 56 and with the requirements for informed consent set forth in part 
50; and  
 
(v) The investigation is conducted in compliance with the requirements of 312.7. ” 
(http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=312.2 ) 
  
 
The presented  background info rmation about the study agent enzalutamide (MDV3100, 
Xtandi) is taken directly from the Enzalutamide Investigators Brochure provided by 
Astaellas Pharma U.S., Inc. : Medivation, Inc. MDV3100 Investigator's Brochure  
23 MAR 20 12 - v5.0 FINAL . More information is provided in the Investigator’s Brochure.  
 
1.2.1 Summary of Pre -Clinical Studies of enzalutamide (MDV3100):  
 
Enzalutamide ( MDV3100 ) is an androgen receptor (AR) signaling inhibitor rationally 
designed to block  multiple s teps in the AR signaling pathway and to be devoid of agonist 
activity. MDV3100  inhibits androgen -induced receptor activation (binding of androgens to 
ARs in the cytosol), inhibits nuclear translocation of activated ARs, and inhibits the 
association of the activated AR with chromatin, even in the setting of AR overexpression 
and in prostate cancer cells resistant to anti -androgens such as bicalutamide. The 
consequence of MDV3100 AR signaling inhibition is decreased growth of prostate cancer 
cells, induction of cancer cell death, and tumor regression.  
 
Safety pharmacology studies in mice, rats, and dogs were performed with MDV3100 to  
assess any acute effects on central nervous system, respiratory, and cardiovascular  
parameters. No MDV3100 -related effects were noted in the central nervous system study  
assessing a functional observation battery and in a respiratory study in rats. MDV3100  
inhibits the human ether -a-go-go-related gene (hERG) channel; however, the highest free  
concentrations of MDV3100 expected in p atient plasma at a steady -state dose of 160 
mg/day are well below the hERG inhibitory concentration 50% (IC50) value. No 
MDV3100 -related effects on cardiac electrophysiology were noted in a safety 
pharmacology study in conscious, telemetered dogs.  
 
As MDV3 100 inhibits the gamma amino butyric acid (GABA) -gated chloride channel,  
convulsion potential was assessed in single - and multiple -dose studies in mice.5 Oral  
MDV3100 daily for 7 days was associated with convulsions in a dose -dependent manner  
with doses ≥ 200 mg/kg being active. When administered as a single dose of 400 mg/kg  
MDV3100 treatment was also associated with convulsions. At the highest dose at which 
no convulsions occurred (single dose, 100 mg/kg), the maximum plasma concentration 
________________________________________________________________________  
7 (Cmax) and area under the curve at 24 hours after dosing (AUC24) were at least 2.5 -
times higher than those in patients receiving 160 mg/day.  
 
MDV3100 is metabolized primarily to 2 metabolites, M1 (a carboxylic acid derivative) and  
M2 (N -desmethyl MDV3100). The metabolite M2 has a pharmacology profile similar to 
that of the parent molecule and may contribute to the therapeutic effects of MDV3100 in 
patients. M2 also binds to and inhibits the GABA -gated chloride channel with potency 
similar to that of the parent molecule and  may contribute to convulsion risk. Metabolite 
M1 does not have significant pharmacological actions and probably does not contribute 
to the therapeutic effects of MDV3100.  
 
Nonclinical Pharmacokinetics and Metabolism  
Following oral administration, MDV3100 has a half -life (t1/2) of approximately 0.25 to  
3 days in mice, rats, dogs, and monkeys. The t1/2 does not appear to be affected by the 
dose size; however, the bioavailability in animals appears to decrease with increasing 
dose size.  
In vitro studies show the following:  
 MDV3100 is metabolized by human recombinant cytochrome P450 (CYP) isoenzymes  
CYP2C8 and CYP3A4/5;  
 MDV3100 and/or its major human metabolites are potential inhibitors of CYP2C8 and  
CYP2C19 with lesser potential for inhibitory effects on C YP2B6 and CYP2C9;  
 MDV3100 is a potential inducer of CYP3A4;  
 MDV3100 is a potential inhibitor, but not a substrate, of the efflux transporter  
permeability glycoprotein (P -gp); 
 The protein binding of MDV3100 in human plasma is 97% to 98% and is similar  in 
mice,rats, rabbits, and dogs;  
 The protein binding of metabolites M1 and M2 in human plasma was 98% and 95%,  
respectively, and was comparable across species. The extent of binding for both  
metabolites was constant over a wide range of concentrations ( 0.5 to 25 μg/mL).  
 
Toxicology  
MDV3100 has been evaluated in nonclinical toxicity studies from single doses up to  
26 weeks of daily dosing, in mice, rats, dogs, and cynomolgus monkeys. Rats and dogs 
were the species chosen for the majority of the toxicity s tudies. The key findings from the  
MDV3100 toxicity studies were as follows:  
 MDV3100 was well tolerated in rats at doses up to 100 mg/kg/day for 26 weeks and in  
dogs at doses up to 20 mg/kg/day for 13 weeks.  
 MDV3100 was well tolerated in cynomolgus monk eys at the highest dose tested,  
100 mg/kg as a single oral dose.  
 Treatment -related mortality occurred in mice given ≥ 400 mg/kg as a single dose  
or ≥ 100 mg/kg/day for 7 days. In repeat -dose studies in rats, mortality was attributed to  
gavage error or ac cidental aspiration of the Labrasol formulation; however, no  
treatment -related mortality was observed at doses up to 200 mg/kg/day. In dogs,  
mortality at 100/60 mg/kg/day was attributed to accidental aspiration of Labrasol, but in  
some cases was of uncerta in relationship to MDV3100.  
 The main findings in repeat -dose oral studies in rats and dogs were MDV3100 -related  
macroscopic findings, microscopic findings, and organ weight changes in reproductive  
and hormone -sensitive tissues. All of these tissues changes were consistent with the  
pharmacological activity of MDV3100. The organs affected, depending on the species or  
duration of dosing, were prostate glands, seminal vesicles, testes, and/or epididymides,  
mammary glands, pituitary glands and adrenal glands. Full or partial reversibilit y was  
noted after treatment -free periods ranging from 4 to 21 weeks.  
 Clinical signs such as salivation (rats and dogs), vomiting, fecal changes (dogs and  
monkeys), and audible respiration (rats and mice) were attributed to the vehicle Labrasol.  
 Central nervous system effects, including decreased motor activity, ataxia, clonic  
convulsions, and/or tremors, occurred in dose range finding toxicokinetic studies in mice  
________________________________________________________________________  
8 given ≥ 400 mg/kg as a single dose or 200 mg/kg/day for 7 days. One instance each of  
convulsions was noted in 1 dog and 1 rat in the good laboratory practice ( GLP) toxicity  
studies.  
 There were no treatment -related adverse clinical pathology findings. Mild changes,  
possibly attributable to the pharmacological activity of MDV3100 were noted, including  
increases in glucose and cholesterol, and decreases in hemato logy parameters (red 
blood cell counts, hemoglobin, and hematocrit).  
 Toxicokinetic evaluations in rats and dogs showed that systemic exposure to MDV3100 
generally increased with increasing dose size, but the increases were less than dose 
proportional. Wi th daily oral administration, the mean accumulation index was  
approximately 1 to 3 in rats and 1 to 4 in dogs. The magnitude of accumulation did not  
appear to increase with the dose.  
 The 2 major human metabolites M1 and M2 were detected in all toxicology  species.  
 MDV3100 was non -mutagenic in bacteria, non -clastogenic in mammalian cells, and  
non-genotoxic in vivo in mice.  
 MDV3100 did not induce phototoxicity in cultured mammalian cells.  
Consistent with the expected pharmacology of MDV3100 to inhibit th e AR signaling  
pathway, the most salient effects of MDV3100 in rats and dogs were on male sex organs.  
Reductions in prostate, epididymis, and/or seminal vesicle weight were observed, and 
these were associated with corresponding histopathological findings o f prostatic and 
seminal vesicle secretory depletion and/or atrophy, and with epididymal atrophy in dogs 
only.  Hypospermatogenesis and degeneration of seminiferous tubules in testes were 
observed in dogs, but not in rats. Females were included in each toxic ity study, except 
the 13 -week  toxicity study in dogs.  
 
Specifically in regards to effects in females, enlarged uteri were noted in 4 - and 26 -week  
repeat -dose studies in rats only, and were considered related to MDV3100. Enlargement 
of the uterine lumen, ob served microscopically, correlated with this finding and was 
reversible.  Mammary glands of both male and female rats were affected histologically by 
MDV3100 in the 26 -week study, though with qualitatively different results. Mild 
glandular/lumen dilationand  mild lobular hyperplasia were observed in females, whereas 
mammary gland atrophy was observed in males. The mammary gland changes persisted 
after an 8 -week recovery period in male and female rats. Mammary gland and uterine 
changes noted in female rats wer e not seen in female dogs in the 4 -week dog study, the 
longest dosing duration studied in female dogs. Histopathological changes definitively 
related to MDV3100 treatment of dogs have been confined to changes in male sex 
organs.  
 
Overall, MDV3100 was gener ally well tolerated in pivotal nonclinical studies with rats and  
dogs with the most prominent effects occurring in reproductive and hormone -sensitive  
tissues.  
 
1.2.2 Summary of human experience with enzalutamide (MDV3100)  
 
The pharmacokinetics (PK), tolera bility, and antitumor activity of MDV3100 were first  
studied in a multi -center, open -label, first -in-human, dose -escalation study of MDV3100 
in 140 patients with castration -resistant prostate cancer (S -3100 -1-01).10 Patients who 
were  chemotherapy -naïve or who had previously failed docetaxel -based chemotherapy 
were  treated with MDV3100 at doses of 30 to 600 mg/day until disease progression or 
intolerable  side effects developed.   
 
MDV3100 was absorbed rapidly after oral administration, with the time to maximum 
plasma  concentration (tmax) after a single dose typically occurring at 1 hour postdose. 
No major  deviations from dose proportionality were observed over the dose range 30 to 
600 mg. Due  to the long t1/2 (~ 5.8 days), it took approximately 1 month to reach steady 
state. With daily  oral administration MDV3100 accumulation was observed at steady 
________________________________________________________________________  
9 state with an 8.3 -fold higher exposure (steady -state area under the curve  [AUC]) relative 
to a single dose. Based  on the mean peak -to-trough ratio, the average difference 
between the peak (Cmax) and trough  (minimum plasma concentration [Cmin]) 
concentrations was ≤ 25%. As a result of the low  daily fluctuations, plasma profiles at 
steady -state res embled a constant infusion. The Cmin  values in individual patients 
remained constant beyond Day 28 of chronic ther apy, suggesting time -linear PK once 
steady state was achieved.   
 
The maximum tolerated dose was determined to be 240 mg daily. MDV3100 
demonstrated  antitumor activity across endpoints in patients both with and without 
previous exposure to  chemotherapy. The  antitumor activity endpoints included prostate -
specific antigen (PSA)  reduction from baseline, median time to PSA progression, 
responses on imaging, and  circulating tumor cell conversion from unfavorable to 
favorable counts. Three potential  MDV3100 -associ ated toxicities were identified in this 
study: fatigue, rash, and seizure.Three seizures (2 witnessed, 1 unwitnessed) occurred in 
this study at doses of 360, 480, and600 mg/day, and were reported between 26 and 48 
days after initiation of MDV3100.  After re view of all data available from the S -3100 -1-01 
study, the optimal dose of MDV3100  for evaluation in Phase 3 clinical trials was 
determined to be 160 mg/day. A Phase 3,  randomized, double -blind, placebo -controlled 
efficacy and safety study of oral  MDV3100 (160 mg daily) in patients with progressive 
castration -resistant prostate cancer  previously treated with docetaxel -based 
chemotherapy (CRPC2, also known as AFFIRM)  was conducted in 1199 men, 800 of 
whom received treatment with MDV3100.11  
 
A formal interim analysis of overall survival was performed at 520 events (80% of the  650 
targeted number of events for final analysis) and demonstrated a statistically -significant  
increase in the duration of survival among patients treated with MDV3100 compared with  
patients treated with placebo (hazard ratio = 0.631 [95% CI: 0.529, 0.752], p < 0.0001).  
Median survival was 18.4 months in the MDV3100 arm and 13.6 months in the place bo 
arm (Δ = 4.8 months). The survival benefit was seen in all pre -specified patient 
subgroups  defined by age, geographic region, Eastern Cooperative Oncology Group 
(ECOG)  performance status, pain score, Gleason score, number of prior chemotherapy 
regimens, type  of disease progression at study entry, baseline level of PSA, baseline 
level of hemoglobin,  and baseline level of lactate dehydrogenase (LDH). There were also 
statistically -significant  increases in time to PSA progression; radiographic progression -
free surv ival (assessed by  computed tomography [CT] or magnetic resonance imaging 
[MRI] and by bone scan); time  to first skeletal -related event; PSA response, and overall 
objective soft tissue radiographic  response among patients treated with MDV3100 
compared to pl acebo. In addition,  statistically -significant differences favoring MDV3100 
over placebo in pain palliation and  pain progression rate at Week 13 were also 
observed.11 
 
Of the MDV3100 -treated patients, 98.1% reported at least 1 treatment -emergent adverse  
event as compared to 97.7% of placebo patients as of the data cutoff date of 25 
September  2011. Serious adverse events were reported in 33.5% of MDV3100 -treated 
patien ts as  compared with 38.6% of placebo -treated patients. Of the MDV3100 -treated 
patients, 7.6%  discontinued study drug due to adverse events as compared with 9.8% of 
placebo patients.   
 
Adverse events reported by those treated with MDV3100 with an incidence at least  2% 
greater than that among those who received placebo included fatigue, diarrhea, hot flush,  
musculoskeletal pain, headache, insomnia, anxiety, hypertension, nasopharyngitis,  
pollakiuria, fall, pruritus, dry skin, and musculoskeletal stiffness. Se rious adverse events  
reported with an incidence of at least 0.5% and more frequently by MDV3100 -treated  
patients compared to placebo patients were spinal cord compression, general physical 
health  deterioration, hematuria, pneumonia, bone pain, metastatic p ain, pathologic 
________________________________________________________________________  
10 fracture, urinary  tract obstruction, cauda equina syndrome, pain, metastases to central 
nervous system, and  urosepsis. The most common adverse events leading to treatment 
discontinuation among  those receiving MDV3100 were fatigue, dysphagia , vomiting, 
nausea, and cerebrovascular  accident, and were reported with incidence between 0.4% 
to 0.6%.  
 
As an inhibitor of the GABA -gated chloride channel, MDV3100 has the potential to cause  
seizures.5 A dose -dependent relationship between MDV3100 exposu re and seizure 
incidence  was seen in both a nonclinical mouse study and the Phase 1 S -3100 -1-01 
study in which  seizures were reported at supra -clinical doses in 3 patients (all with other 
seizure risk factors  such as use of concomitant medication that may lower seizure 
threshold). Seizures have also  been reported at the 160 mg dose; however, there were 
confounding factors that may have  contributed to the occurrence of seizures in the 
majority of these cases. In the Phase 3  CRPC2 study, seizures were reporte d in 5 (0.6%) 
patients treated with MDV3100 (160 mg  daily) and no placebo patients as of the data 
cutoff date of 25 September 2011. Two of these  patients had brain metastases, 1 had 
inadvertently received an intravenous lidocaine  overdose, 1 had recently i nitiated 
haloperidol in the context of heavy alcohol use with brain  atrophy, and 1 had cortical 
atrophy with microvascular disease. These observations suggest  that MDV3100 may 
lower the seizure threshold at the clinical dose of 160 mg daily. Overall,  MDV31 00 (160 
mg daily) was well -tolerated in the CRPC2 study.  
 
1.3 Other Agents  
Synthetic peptide analogs of gonadotropin releasing hormone (GnRH) are FDA approved 
for palliative treatment of advanced prostate cancer. In addition, there is category 1 
evidence to su pport the use of GnRH agonists in combination with an antiandrogen and 
radiation therapy for the treatment of patients with high -risk localized or locally advanced 
prostate cancer (NCCN Guidelines Version 1.2013). GnRH agonist treatment is a form of 
androg en deprivation therapy (ADT). In the current study, subjects will receive treatment 
with an approved GnRH agonist, leuprorelin acetate (administered as an intramuscular). 
Planned treatment duration will be for 2 - 3 years , at the discretion of the treating  
physician and the patient . Adverse effects associated with GnRH agonist treatment 
include diminished libido, hot flashes, hot flushes, gynecomastia, osteoporosis, increased 
incidence of fracture, obesity, alterations in serum lipid levels, insulin resista nce, 
increased risk for development of diabetes mellitus, and increased risk for cardiovascular 
disease (NCCN Guidelines Version 1.2013).  
 
1.4 Rationale  
Prostate cancer is the leading cause of non -skin cancer in the United States, with an 
estimated 241,740 ne w cases diagn osed in 2012.12 It is the number two  cause of 
prostate cancer m ortality among men in the US, accounting for 28,170 deaths.12 The 
majority o f these deaths are attributed to metastatic prostate cancer that is resistant to 
castration. Castration, defined as a serum testosterone level < 50 ng/dL, has been the 
mainstay of intervention for metastatic prostate cancer for decades. Castrate -levels of 
testosterone are achieved surgically through bilateral orchiectomy, or alternatively 
through treatment with administration of GnRH ago nists or antagonists. Castrate -
resistant prostate cancer (CRPC) often continues to rely on signaling through the 
androgen receptor that can be maintained even at very low (castrate) levels of circulating 
androgens. The androgen receptor signali ng inhibitor enzalutamide  has demonstrated 
activity against prostate cancer cells that overexpress the androgen receptor and are 
resis tant to earlier generation anti -androgens such as bicalutamide.13,14 Enzalutamide is 
well-tolerated and is FDA-appro ved for use in combination with castration  therapy for the 
________________________________________________________________________  
11 treatment of patient s with metastatic CRPC who have experienced disease progression 
despite docetaxel chemotherapy.11  
 
Several predictors enable us to identify patients with localized prostate cancer who are at 
highest risk to develop metastatic CRPC. These include serum prostate specific antigen 
(PSA ), Gleason score, and clinical tumor (T)  stage on physical  examination. Patients with 
high-risk localized, or locally advanced (those with radiographic or biopsy -demonstrated 
evidence of pelvic lymph node involvement) prostate cancer are routinely treated with a 
combination of GnRH agonist, first-generation anti-androgen, and EBRT. Androgen 
deprivation therapy (ADT) combined with radiation therapy has demonstrated superior 
survival outcomes when compared to either ADT or EBRT alone.1-9 Standard of care 
treatment of men with high -risk localized or locally -advanced prostate cancer who receive 
external beam radiation therapy is 2 -3 years of androgen deprivation therapy with a 
GnRH agonist , with concurrent treatment with a first -generation anti -androgen for the 
initial 4 -6 months . EORTC 22961 demonstrated an improvement in 5 year overall survival 
for men with locally advanced prostate cancer treated with EBRT plus 6 months of GnRH 
agonist therapy plus a first -generation anti -andro gen, followed by 30 months of GnRH 
agonist treatment alone, compared to this treatment without the additional 30 months of 
GnRH agonist therapy.2 However, since many  of these high-risk patients will go on to 
develop metastatic prostate cancer , there remain s a significant need to impr ove upon the 
current treatment. No trial to date has tested the combination of e nzalutamide  with GnRH 
agonist therapy and external beam r adiation therapy (EBRT) for patients with high -risk 
localized or locally -advanced prostate cancer . We hypothesize that this combination will 
be safe and well -tolerated. Once the safety profile has been established, we hypothesize 
that this combination  may provide superior androgen signaling suppression and prostate 
cancer cell cytotoxicity compared to a first -generation anti -androgen plus GnRH agonist 
and improve clinical outcomes.  
 
This pilot study will assess the safety and tolerability of combining enzal utamide with 
GnRH agonist treatment and EBRT. We hypothesize that administration of enzalutamide 
plus a GnRH agonist for 6 months in combination with EBRT, followed by treatment with 
a GnRH agonist alone for 18 - 30 months, will be a safe and well -tolerate d treatment for 
patients with high -risk localized or locally advanced prostate cancer. We will perform 
correlative imaging and tumor tissue biopsy analysis to assess the radiographic response 
to enzalutamide plus GnRH therapy as well as intratumoral androg en signaling.  
 
The primary endpoint is to determine the safety and tolerability of combining enzlutamide 
plus a GnRH agonist with EBRT up to 12 months following initiation of treatment with 
enzalutamide plus GnRH agonist. Primary endpoint measures are fre quency of AEs with 
monitoring for  
1. Expected toxicities specific to the combination of enzalutamide plus GnRH 
agonist based on the clinical experience with this FDA -approved combination for the 
treatment of metastatic castration -resistant prostate cancer  as annotated in section 1.2.2  
2. Expected radiation -related toxicities as annotated in section 4.4.1.8  
3. Unexpected severe AEs due to combination of enzalutamide plus GnRH agonist with 
EBRT.  
 
Secondary endpoints will include  
 
1. Molecular markers of a ndrog en signaling and cell proliferation  in prostate biopsy 
samples  
a. Inhibition of androgen -regulated gene expression (potential  targets to 
include NDRG1, FKBP5, TMPRSS2, and PSA) by qRT -PCR  
b. Inhibition of androgen receptor (AR) nuclear localization and prostat e 
cancer cell proliferation measured by immunohistochemistry (IHC)  
c. Androgen metabolism in prostate biopsy samples  
________________________________________________________________________  
12 2. Serum PSA and  testosterone following combination therapy with enzalutamide plus 
GnRH agonist therapy prior to initiation of radiation therapy  
3. Changes in prostate tumor volume and activity following 2 months of combined 
enzalutamide plus GnRH therapy compared to baseline as measured by multi -
parametric magnetic resonance imaging (MRI)  
   
These results will lay the groundwork for subsequent random ized trials to compare this 
treatment combination with the current standard of care in patients with high -risk 
localized and locally -advanced prostate cancer.  
 
1.5 Correlative Studies  
In pre -clinical studies,  enzalutamide was shown to inhibit  androg en receptor  signaling 
through multiple mechanisms .13,14 Enzalutamide inhibits androgen -induced receptor 
activation (binding of androgens to ARs in the cytosol), inhibits nuclear translocation of 
activated ARs, and inhibits the association of the activated AR with chromatin, even in 
the setting of AR overexpression and in prostate cancer cells resistant to anti -androgens 
such as bi calutamide.  However, inhibition of AR signaling by enzalutamide has not been 
reported  directly in primary patient tumor samples. We hypothesize that enzalutamide will 
impair AR nuclear localization and expression of AR -regulated genes in human tumors 
when administered in combination with GnRH agonist treatment. We hypothesize that 
this treatment combination will also result in a measurable anti -tumor response by muli -
parametric magnetic resonance imaging (MRI).  
 
To test these hypotheses, we will obtain pros tate cancer tumor biopsies at the time of 
study enrollment and following two months of treatment with enzalutamide plus GnRH 
agonist. MRI of the pelvis, protoco lled to assess the prostate, will be performed prior to 
the initial biopsy and again prior to th e subsequent biopsies obtained following two 
months of treatment.  
 
2.0 STUDY OBJECTIVES  
 
2.1 Primary Objectives  
 
2.1.1  To determine the safety and tolerability of combining enzalutamide 160 mg by 
mouth daily with a GnRH and EBRT. Enzalutamide and GnRH agonist will  be 
administered in combination for 6 months, beginning two months prior to the start 
of EBRT. Enzalutamide and GnRH agonist treatment will continue for the 
duration of EBRT and for approximately two months after completion of EBRT, 
for a total of 6 months  of combined enzalutamide plus GnRH treatment. Patients 
will subsequently receive an additional 18 - 30 months of GnRH agonist therapy 
for a total of two - three years of GnRH agonist treatment. Safety and tolerability 
will be assessed by frequency and sev erity of adverse events with monthly 
monitoring for 12 months following initiation of enzalutamide plus GnRH therapy.  
Secondary Objectives  
 
2.1.2  To determine whether enzalutamide combined with GnRH agonist treatment 
inhibits intra -tumoral androgen -regulat ed gene expression (potential  targets to 
include NDRG1, FKBP5, TMPRSS2, and PSA) as measured by qRT -PCR  
 
________________________________________________________________________  
13 2.1.3  To determine whether enzalutamide combined with GnRH agonist treatment 
impairs androgen receptor nuclear localization  and cancer cell proliferat ion in 
targeted prostate cancer biopsy samples.  
 
2.1.4  To determine the impact of enzalutamide combined with GnRH agonist on 
androgen metabolism in prostate biopsy samples . 
 
2.1.5  To determine the impact of enzalutamide plus GnRH agonist therapy on serum 
prostate specific antigen (PSA ) and testosterone  following two months of 
treatment . 
 
2.1.6  To describe any preliminary evidence of anti -tumor activity by assessment of 
objective response as determined by multiparametric MRI in patients with high-
risk locali zed or locally -advanced prostate cancer.  
2.2 Exploratory Objectives  
Exploratory objectives are those defined above as secondary objectives 2.1.2 – 2.1.4.  
2.3 Endpoints  
2.1.1  Safety and tolerability will be assessed based on the rate of drug -related grade 1 -
5 adve rse events  experienced within the first 12 months  of study treatment . These will be 
assessed via NCI’s CTCAE v 4.0 toxicity criteria .  
 
2.1.2  Molecular markers of androgen -regulated gene expression in tumor biopsy 
samples will be assessed by qRT -PCR at the time of study initiation and following two 
months of combined treatment with enzalutamide plus GnRH agonist.  
 
2.1.3  Androgen receptor nuclear localization  and cancer cell proliferation (using Ki -67) 
will be analyzed by immunohistochemical analysis of tumo r biopsy samples at the time of 
study initiation and following two months of combined treatment with enzalutamide plus 
GnRH agonist.  
 
2.1.4  Enzymes of androgen metabolism will be assessed from prostate tumor biopsy 
specimens by qRT -PCR  
 
2.1.5  Serum levels of prostate specific antigen (PSA) and  testosterone  will be 
measured at study initiation and fol lowing two months of treatment with enzalutamide 
combined with GnRH agonist.  
 
2.1.6  Changes in prostate tumor volume and tumor activity will be measured by 
magn etic resonance imaging (MRI) at the time of study initiation prior to the initial study 
biopsy and again following two months of combined enzalutamide plus GnRH agonist 
treatment just prior to the second study biopsy to be performed at the time of fiducial  
marker placement.  
 
3.0 Subject  ELIGIBILITY  
Eligibility waivers are not permitted.  Subjects must meet all of the inclusion and exclusion criteria 
to be registered to the study.  Study treatment may not begin until a subject is registered.  
3.1 Inclusion Criteria  
 
3.1.1  Histologically proven adenocarcinoma of the prostate obtained within 6 months of 
screening. Patients in whom a diagnosis of high -risk localized or locally -
advanced prostatic adenocarcinoma is suspected based on a serum PSA > 20 
________________________________________________________________________  
14 ng/mL or clinical T3 disease  by digital rectal examination , but who have not yet 
undergone diagnostic prostate biopsy,  will be eligible for screening and initial 
MRI and targeted prostate cancer biopsies which will be obtained at the same 
time as diagnostic biopsies. Those patients i n whom the diagnostic biopsies 
confirm  prostatic adenocarcinoma will be permitted to continue with study 
treatment if they meet all additional eligibility criteria.  
 
3.1.2  Age ≥ 18 years.  
 
3.1.3  Eastern Cooperative Oncology Group (ECOG) p erformance status  < 2 
 
3.1.4  Adequat e organ and marrow function as defined below:  
- leukocytes    ≥ 3,000/mcL  
- absolute neutrophil count  ≥ 1,500/mcL  
- platelets    ≥ 100,000/mcl  
- hemoglobin   > 10 g/dL  
- total bilirubin   < 1.5 X institutional upper limit of normal (except 
for patients with do cumented Gilbert’s disease)  
- AST(SGOT)/ALT(SPGT)  ≤ 2.5 X institutional upper limit of normal  
- creatinine  < 1.5 X institutional upper limit of normal  or 
estimated glomerular filtrat ion rate < 45 
mL/min/1.73m2 , given the risk o f nephrogenic 
systemic fibros is when using gadolinium -based 
intravenous contrast agents in these subjects.  
- serum testosterone  > 100 ng/dL  
  
3.1.5  Men who are sexually active with female partners of child -bearing potential must 
agree to use adequate contraception (hormonal or barrier metho d of birth control; 
abstinence) prior to study entry, for the duration of study participation, and for 90 
days following completion of therapy . Should a woman become pregnant or 
suspect she is pregnant following intercourse with a study participant during his 
participation in this study, she should inform her  treating physician immediately, 
and the study principal investigator should be informed immediately.  
 
3.1.6.1  A female of child -bearing potential is any woman (regardless of sexual 
orientation, having undergone a tubal ligation, or remaining celibate by 
choice) who meets the following criteria:  
 
 Has not undergone a hysterectomy or bilateral oophorectomy; or  
 Has not been naturally postmenopausal for at least 12 consecutive 
months (i.e., has had menses at  any time in the preceding 12 
consecutive months).  
 
3.1.6  Patients must be candidates for long -term androgen deprivation in combination 
with EBRT for the treatment of high -risk or locally -advanced prostate cancer by 
the following criteria:  
 High risk disease: T3a  or Gleason 8 -10 or serum PSA > 20 ng/mL  
 Gleason 7 also allowed if > 50% of cores positive for cancer or PSA velocity 
> 2 ng/mL/year in preceding 12 months  
 Locally advanced (very high risk) disease: T3b -T4 
 
3.1.7  Patients may have radiographic evidence of metast asis in regional lymph nodes (N1 
disease as defined by the National Comprehensive Cancer Network Prostate Cancer 
Guideline Vers ion 3.2012) at the discretion of the treating physicians, if regional 
lymph nodes can be included in the planned radiation field.  
________________________________________________________________________  
15 3.1.8  Participants in the study must permit targeted prostate biopsy prior to initiation of 
study treatment and at the time of fiducial marker placement  
3.1.9  Able and willing to provide written authorization for use and release of health and 
research study informati on 
 
3.1.10  Ability to understand and the willingness to sign a written informed consent.  
3.2 Exclusion Criteria  
 
3.2.1  Prior treatment with the following agents known to have endocrine effects on 
prostate cancer: GnRH agonist, GnRH antagonist, anti -androgen (bicalutamide, 
nilutamide, flutamide), ketoconazole, diethylstilbestrol, estrogen, abiraterone 
acetate . Concurrent use of 5 -reductase inhibitors finasteride or dutasteride is 
permitted for patients who have been already receiving either of these treatments 
for at least 1 month at the time of study enrollment . Baseline PSA must have 
been obtained in such patients after at leas t 1 month on 5 -reductase treatment. 
Initiation of treatment with 5 -reductase inhibitors is not permitted within the first 
12 months of study participation.  
 
3.2.2  Concomitant treatment with agents thought to have endocrine effects on prostate 
cancer: PC -SPES,  saw palmetto  
3.2.3  Treatment with corticosteroids within 4 weeks prior to enrollment . 
3.2.4  Treatment with androgens within 6 months prior to study enrollment.  
3.2.5  Subjects  may not be receiving any other investiga tional agents. Concurrent 
enrollment in another clinical i nvestigational drug or device study is prohibited.  
3.2.6  Prostate cancer metastases to the bones, viscera, or non -regional lymph nodes 
(lymph nodes other than pelvic lymph nodes within the radiation treatment field)  
3.2.7  Serum PSA > 160 ng/dL  
3.2.8  History of malignancy (o ther than non -melanoma skin cancer) within 5 years of 
enrollment  
3.2.9  Patients with histologic evidence of small cell carcinoma of the prostate will not 
be eligible.  
 
3.2.10  Treatment for malignancy with anticancer therapy, including cytotoxic agents, 
hormonal agents , or immunotherapy, within 5 years of enrollment  
 
3.2.11  History of allergic reactions attributed to compounds of similar chemical or 
biologic composition to  enzalutamide or other agents used in  this study.  
 
3.2.12  Uncontrolled intercurrent illness including, but not li mited to, ongoing or active 
infection, symptomatic congestive heart failure  (> NYHA class II hear failure) , 
unstable angina pectoris, cardiac arrhythmia, chronic active hepatitis, acute 
hepatitis, uncontrolled diabetes mellitus, or psychiatric illness/soci al situations 
that would limit compliance with study requirements.  
3.2.13  Patients with any of the following within 6 months of enrollment: deep vein 
thrombosis, pulmonary embolus, myocardial infarction, cerebrovascular accident, 
unexplained loss of consciousness . 
________________________________________________________________________  
16 3.2.14  Patients with any history of seizure or seizure disorder . 
3.2.15  Patients with medical conditions which, in the opinion of the investigators, would 
pose undue risk to the patient  
 
3.2.16  Subjects unwilling to use contraceptives if they have sexual intercourse with a 
female partner of child -bearing potential while receiving treatment on this study . 
3.2.17  Standard c ontraindications to MRI: For example, MRI non -compatile cardiac 
pacemakers, intracranial clips, foreign metal objects in the body and others as 
defined in the UT So uthwestern Institutional MRI Safety Policy ) 
3.2.18  The following medications are prohibited during the study:  
 Substrates of CYP2B6, CYP2C8, CYP2C9, and CYP2C19 with a narrow 
therapeutic index, including paclitaxel, phenytoin, warfarin, omeprazole   
 Substrates of CYP3A4 with a narrow therapeutic index, including alfentanil, 
cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, 
sirolimus, tacrolimus  
 Strong CYP2C8 inhibitors, including gemfibrozil  
 Strong CYP3A4/5 inhibitors, including clarithrom ycin, itraconazole, 
ketoconazole  
 
4.0 TREATMENT PLAN  
4.1 Treatment Dosage and Administration  
 
4.1.1  We propose a single -institution, single -arm study of neo -adjuvant, concomitant, 
and adjuvant enzalutamide plus GnRH agonist with external beam radiation 
therapy for  the treatment of patients with high -risk and locally -advanced prostate 
cancer.  
 
4.1.2  Eligible study participants will receive treatment with enzalutamide 160 mg daily 
for 6 months in combination with GnRH agonist treatment. Following the initial 
two mon ths of treatment with enzalutamide and GnRH agonist, radiation therapy 
will be administered as detailed below. GnRH agonist treatment will be continued 
for a total treatment duration of 24 - 36 months  at the discretion of the treating 
physician in concert with the patient . Treatment will be administered on an 
outpatient basis.  
 
 
 
Table 4.1  
Agent   
Dose   
Route   
Schedule  
Enzalutamide  160 mg daily (four 40 
mg capsules ) p.o.  Daily for 6 months  
Leuprolide acetate  22.5 mg every 3 months  
 
or 
 
45 mg every 6 month s IM  Every 3 or 6 months 
(depending on dosage 
form used) for a total 
treatment duration of 
24-36 months  
 
 
________________________________________________________________________  
17 A study medication diary will be provided to each subject in which daily oral self -
administration of enzalutamide will be documented. If a dose is m issed, enzalutamide 
should be resumed the next day at the established daily dose of 160 mg. A vomited dose 
should not be replaced.  
 
4.2 Toxicities and Dosing Delays/Dose Modifications  
Any subject  who receives treatment on this protocol will be evaluable for to xicity . Each 
patient will be assessed for the development of toxicity according to the Time and Events 
table ( Table 5.4 ). Toxicity will be assessed according to the NCI Common Toxicity 
Criteria for Adverse Events (CTCAE), version 4.0. Dose adjustments shou ld be made 
according to the system showing the greatest degree of toxicity .  
 
Enzalutamide (Xtandi, MDV3100) has been shown to be well -tolerated when used in 
combination with androgen deprivation (in the form of GnRH agonists or castration by 
orchiectomy) in completed phase I, II, and III clinical trials.  
 
Table 4.2.1 Hematological Toxicity Dose Reductions for Enzalutamide  
ANC  Platelets  Action  
≥ 1,500/L 100,000/ L None.  
 
1000 -1499/L  
75,000 -99,000/L -1st Occurrence: Hold current dose until ANC ≥ 
1,500 /L and platelets ≥ 100,000/ L. Do not 
replace missed doses . Restart next treatment at 
120 mg  dose.  
-2nd Occurrence :Hold current dose until ANC ≥ 
1,500/L and platelets ≥ 100,000/ L. Do not 
replace missed doses . Restart next treatment at 
80 mg  dose.  
-3rd Occurrence:  Discontinue protocol therapy.  
 
500-999/L  
50,000 -74,000/L -1st Occurrence :Hold current dose until ANC ≥ 
1,500/L and platelets ≥ 100,000/ L. Do not 
replace missed doses . Restart next treatment at 
120 mg  dose.  
-2nd Occurrence : Discontinue p rotocol therapy.  
 
<500/L  
<50,000/ L  
-1st Occurrence : Discontinue protocol therapy.  
 
 
Table 4.2.2. Non-hematological Toxicity Dose Reductions  
NCI CTC Grade  Enzalutamide  
0-2 No change from original starting dose (with the exception of seizure)  
3-4 Hold until resolved to <Grade 2, then reduce to 120 mg dose  
Second episode of 
grade 3 or 4 toxicity  Hold until resolved to <Grade 2, then reduce to 80 mg dose  
Third episode of 
grade 3 or 4 toxicity  Remove subject from trial  
________________________________________________________________________  
18  
In the randomized clinical tr ial of patients with docetaxel -refractory metastatic CRPC, 7 of 800 patients 
(0.9%) treated with enzalutamide 160 mg daily experienced a seizure. No seizures occurred in patients 
treated with placebo. Patients experiencing seizures were permanently discont inued from therapy and all 
seizures resolved. There is no clinical trial experience re -administering enzalutamide to patients who 
experienced seizures. Therefore, should a subject experience any seizure, enzalutamide will be 
discontinued and the subject re moved from the trial.  
 
4.3 Concomitant Medications/Treatments  
In vitro studies show that enzalutamide and/or metabolite M2 are potential inhibitors of  
CYP2C8 and CYP2C19 with lesser potential for inhibitory effects on CYP2B6 and 
CYP2C9.  Enzalutamide is a moder ate CYP2C9 and CYP2C19 inducer in humans. For 
this study, s ubstrates of CYP2B6, CYP2C8, CYP2C9, and CYP2C19 that have a narrow 
therapeutic  index (e.g., paclitaxel, phenytoin, warfarin , omeprazole ) are prohibited.   
 
In vitro studies show that enzalutamide i s an inducer of CYP3A4. Induction of CYP3A 
occurs  via activation of the nuclear pregnane X receptor (PXR), which is expected to 
result in  co-induction of CYP2C. Co -administration of enzalutamide  with CYP3A or 
CYP2C substrates  may reduce oral bioavailabilit y and/or accelerate elimination of these 
substrates.  Enzalutamide is a strong CYP3A4 inducer in humans. For this study, 
concomitant use of enzalutamide with narrow therapeutic index drugs that are 
metabolized by CYP3A4 (e.g., alfentanil, cyclosporine, dihy droergotamine, ergotamine, 
fentanyl, pimozide, quinidine, sirolimus and tacrolimus) is prohibited.  
 
In vitro studies show that enzalutamide is metabolized by CYP2C8 and CYP3A4/5. 
Strong  inhibitors or inducers of these enzymes may affect enzalutamide  exposu res. Co -
administration of a strong CYP2C8 inhibitor (gemfibrozil) increased the composite area 
under the plasma concentration -time curve (AUC) of enzalutamide plus N -desmethyl 
enzal utamide in healthy volunteers. For this study, c o-administration of enzalut amide and 
strong CYP2C8 inhibitors (e.g., gemfibrozil) is prohibited. Co -administration of a strong 
CYP3A4 inhibitor (itraconazole) increased the composite AUC of enzalutamide plus N -
desmethyl enzalutamide by 1 .3 fold in healthy volunteers. For this study,  strong inhibitors 
of CYP3A4/5  (e.g., clarithromycin, itraconazole, ketoconazole) are prohibited during 
enzalutamide  treatment . 
 
Use caution when co -administering strong inducers of CYP2C8 (e.g., rifampin) or  
CYP3A4/5 (e.g., carbamazepine, phenytoin, rifam pin, St. John’s wort) during 
enzalutamide  treatment, as enzalutamide concentrations may decrease.  
 
In vitro studies show that enzalutamide and metabolite M2 are potential inhibitors of the 
efflux  transporter P -gp. Co -administration of enzalutamide with P -gp substrates may 
increase the  plasma concentrations of the P -gp substrate. Use caution when co -
administering sensitive  P-gp substrates (e.g., colchicine, dabigatran etexilate, digoxin) 
during enzalutamide treatment.  
 
Food has no clinically significant effe ct on the extent of absorption. Enzalutamide may be 
taken  with or without food.  
 
Osteoporosis is a potential adverse effect of GnRH agonist therapy. As per the NCCN 
Prostate Cancer Guidelines Version 1.2013, screening and treatment for osteoporosis 
are rec ommended according to guidelines for the general population provided by the 
National Osteoporosis Foundation ( www.nof.org ). It is advised that subjects enrolled in 
this study be treated for osteoporosis at the discretion of the investigator according to 
NOF guidelines. These recommendations include treatment with supplemental calcium 
(1200 mg daily) and vitamin D3 (800 -1000 IU daily) for all men > 50 years of age and 
________________________________________________________________________  
19 additional treatment for men with a 10 year probability of hip fracture  > 3% or 10 year 
probability of a major osteoporosis -related fracture > 20% as assessed using the FRAX 
algorithm established by the World Health Organization. Using the FRAX algorithm, 
GnRH agonist treatment should be considered a secondary osteoporosis risk factor. 
Osteoporosis reatment options permitted in conjunction with this study for appropriate 
patients include denosumab 60 mg SQ every 6 months x 6 doses, zoledronic acid 5 mg 
iv annually, or alendronate 70 mg PO weekly.  
 
Medications kn own to lower the seizure threshold include but are not limited to:  
 Aminophylline/theophylline;  
 Atypical antipsychotics (e.g., clozapine, olanzapine, risperidone, ziprasidone);  
 Bupropion;  
 Lithium;  
 Pethidine (meperidine);  
 Phenothiazine antipsychotics (e.g., chlorpromazine, mesoridazine, thioridazine);  
 Tricyclic and tetracylic antidepressents (e.g., amitriptyline, desipramine, doxepin, 
imipramine, maprotiline, mirtazapine).  
 
4.4 Other Modalities or Procedures  
4.4.1  RADIATION THERAPY  
Radiotherapy should begin with in 8-10 weeks (+/- 7 days)  after the date of the Gn RH and 
enzalutamide administration.injection. Radiotherapy will be administered as standard of care 
treatment.  
 
4.4.1.1. Plan 1 : Whole pelvis including prostate and seminal vesicles  
Acceptable Treatment Mo dalities:  
3D-CRT or IMRT. For patients with N1 disease, only IMRT plan will be allowed.  
 
Prescription Dose (See Table 4.4.1.1):  
45 Gy to cover 98% (+/- 3%) of PTV  
 Minimum dose within PTV – 95% (+/- 5%) of prescribed dose and for a volume that is 0.03 cc  
 Maximum dose within the PTV – 107% (+/- 3%) of prescribed dose and for a volume that is  
0.03 cc  
 
In patients with N1 disease, PTV -N will be defined:  
Prescription dose (See table 4.4.1.2)  
55 Gy to cover 95 %  (+/- 5%) of PTV -N 
 Minimum dose within PTV – 93% (+/- 3%) of prescribed dose and for a volume that is 0.03 cc  
 Maximum dose within the PTV – 105%  (+/- 5%) of prescribed dose and for a volume that is  
0.03 cc  
 
Table 4.4 .1.1: Radiation Therapy Dose Objectives for Plan 1 – Pelvic and Prostate Radiation  
PTV d ose 
(encompassin
g 98% PTV  
(+/- 3%)) Minimu
m PTV 
dose for 
a point 
with a 
volume 
of .03cc  Maximu
m PTV 
dose for a 
point 
with a 
volume 
of .03cc  Maximum 
PTV dose 
to a 
volume of 
.03 cc of 
PTV  
(variation 
acceptable
) Maximum 
PTV dose to 
a volume of 
.03 cc of 
PTV  
(Deviation 
unacceptabl
e 
45 Gy  42.8 Gy  48.2 Gy  > 48.2 -
49.5 Gy  >49.5 Gy  
 
________________________________________________________________________  
20 *Maximum dose must not be within an organ at risk (OAR) such as the rectum, bladder.  
 
Table 4.4 .1.2: Radiation Therapy Dose Objectives for Plan 1 – PTV -N 
PTV -N dose  
(encompassin
g 95% PTV  
(+/- 3%)) Minimu
m PTV -
N dose 
for a 
point 
with a 
volume 
of .03cc  Maximu
m PTV -N 
dose for a 
point 
with a 
volume 
of .03cc  Maximum 
PTV -N 
dose to a 
volume of 
.03 cc of 
PTV  
(variation 
acceptable
) Maximum 
PTV -N dose 
to a volume 
of .03 cc of 
PTV  
(Deviation 
unacceptabl
e 
55 Gy  50.06 
Gy* 60.05 Gy  > 57.75 -
60.05 Gy  >60.05 Gy  
*if PTV -N is adjacent to small bowel, minimum acceptable PTV -N dose will be dose that can be 
achieved while meeting absolute small bowel dose constraints.  
 
4.4.1.2. Plan  2: Reduce volume cone down boost plan to the prostate and (proximal) seminal 
vesicles  
Acceptable Treatment Modalities:  
IMRT or 3DCRT  
 
Table 4.4.2 : Radiation Therapy Dose Objectives for Plan 2 – Prostate and Seminal Vesicle Boost  
PTV dose  
(encompassin
g 98% PTV  
(+/- 3%)) Minimu
m PTV 
dose for 
a point 
with a 
volume 
of .03cc  Maximu
m PTV 
dose for a 
point 
with a 
volume 
of .03cc  Maximum 
PTV dose 
to a 
volume of 
.03 cc of 
PTV  
(variation 
acceptable
) Maximum 
PTV dose to 
a volume of 
.03 cc of 
PTV  
(Deviation 
unacceptabl
e 
34.2 Gy  32.49 Gy 37.62 Gy > 36.6 -
37.6 Gy  >37.6 Gy  
Maximum dose must not be within an OAR such as rectum, or bladder.  
 
4.4.1.3 Technical Factors  
Either 3DCRT or IMRT may be used for treatment. For 3DCRT treating the whole pelvis (WPRT), 
a minimum of 4 -fields should be used and a 4 field plan is recommended. For IMRT, no specific 
field arrangement is required. RT will be delivered with megavoltage equipment at energies ≥ 6 
MV. Typically, except for VMAT techniques, 5 to 9 gantry angles are employed for the IMRT 
treatments.  W hen using IMRT, preference will be given to using photon energies <=10MV, but 
higher energies will be permitted if necessary for production of a more optimal plan due to 
anatomic constraints.  
4.4.1.4 EBRT Localization, Simulation, and Immobilization  
Simula tion will be CT -based in all cases. A urethrogram or MRI is recommended, but not 
required, to be used for target delineation. Rectal contrast is discouraged because it may distend 
the rectum and artificially displace the prostate in the anterior direction.  Intravenous contrast is 
permitted but not required to assist in identifying the pelvic vessels. Patients will be positioned 
supine or prone on a flat tabletop with a customized thermoplastic immobilization cast or a 
molded foam cradle or similar immobiliz ation for stabilization and setup reproducibility. The 
degree of bladder fullness should be made to duplicate the degree of fullness anticipated for daily  
treatment, i.e., if the patient is instructed to maintain a full bladder for treatment, he should be  
simulated as such (especially for cases in which image guidance is not implemented). The rectum  
should be kept as empty as possible; recommendation is for an enema 1 -2 hours prior to 
simulation. CT  images should be acquired at a slice thickness of ≤3 mm from L3/L4 vertebral 
________________________________________________________________________  
21 body to the perineum inferiorly. If Calypso beacons are used, slice thickness of 1.5 -2 mm will be 
recommended. Target volumes and normal critical structures (as defined in section  4.4.1 .5.3)  will 
be defined in the slices in which they are visualized. The 3DCRT cases must utilize “beam’s eye 
view” representations to define final beam aperture.  
 
4.4.1.5 Treatment Planning/Target Volumes  
4.4.1 .5.1 Patients must have a composite treat ment plan generated at the beginning of Plan 1 so 
that the final EBRT dose to critical structures is evaluated before any dose delivery has begun. 
Dose for initial treatment (CTV1/PTV1) will be 45.0 Gy at 1.8 Gy per fraction.  If patient has N1 
disease, CT V-N/PTV -N will be defined, and will received 55 Gy at 2.2 Gy per fraction during plan 
1of the treatment course using simultaneous integrated boost technique (SIB).  All patients with 
N1 disease will be treated with IMRT, and 3DCRT will not be permitted. On ce this portion is 
completed, a cone down boost to the prostate and (proximal) seminal vesicles will be delivered  
by either IMRT or 3DCRT.  Brachytherapy boost is not permitted on this study. For the boost, the 
dose to the CTV2/PTV2 will be 34.2 Gy at 1.8  Gy per fraction, for a total prostate dose of 79.2 
Gy.  For pelvic 3D -CRT, a 4 -field technique, using opposed anterior -posterior and opposed lateral 
fields, is recommended. All fields should conform to the beam’s -eye-view of the target. No 
specific field arrangement is required for IMRT, although typically 5 -9 fields are used for fixed 
gantry treatment. Tomotherapy and VMAT/rapid arc/ smart arc IMRT technologies) also are 
allowed for IMRT treatment on this protocol.  
4.4.1 .5.2. The definition of GTV, CTV an d PTV will be in accordance with the ICRU Report #50:  
Prescribing, Recording, and Reporting Photon Beam Therapy.  
 
4.4.1 .5.2.1 Plan 1 Pelvis, including prostate and seminal vesicles  
Gross Target Volume (GTV1 and GTV -N) 
The GTV1 is defined by the physician a s all known disease as defined by the planning CT, 
urethrogram, MRI, and clinical information. If a urethrogram is used, the GTV will encompass a 
volume inferiorly 5 mm superior to the tip of the dye and no less than the entire prostate. Prostate 
dimension s should be defined as visualized on CT scan. If MRI is performed, fusion of planning 
CT with the MRI will be performed on the treatment planning system, and MRI will be utilized to 
help further refine and delineate the GTV.   
 
GTV-N will be defined as all  positive pelvic nodal disease > 1.5 cm in short axis diameter seen on 
CT scan or MRI before initiation of hormone therapy.  Nodal disease will be contoured based on 
the pre -hormone therapy imaging studies.  If necessary, a CT simulation can be performed p rior 
to initiation of hormone therapy as a baseline study that can be used for treatment planning 
purposes.   At the discretion of the treating physician, nodal disease >=1cm will also be 
considered for GTV -N, particularly if there are multiple gross nodal  disease present.  
 
Clinical Target Volume (CTV1)  
The CTV1 will include the prostate and entire seminal vesicles (SV), the obturator, external iliac, 
proximal internal iliac and distal common iliac nodes, using the vascular structures, up to a level 
corresp onding to the top of L5 -S1. At the treatment team’s discretion, coverage can be in creased 
to include common iliac nodes  up to L4/L5 level. One can refer to the pelvic nodal atlas at the 
RTOG Web site (Pelvic Lymph Node Volumes for Prostate Cancer Atlas; 
http://www.rtog.org/CoreLab/ContouringAtlases/ProstatePelvicLymphNodes.aspx ). 
The presacral nodes from L5 -S1 to S3 may be included if desired depending on whether the dose 
constraints to the re ctum are achievable (see Table 4.4 .3).  The CTV1 will include a 7  mm margin 
in 3-dimensions to the contoured iliac vessels, but not extend outside of the true pelvis, into the 
pelvic musculature nor into adjacent identifiable organs, such as the bladder, rectum or other 
bowel. Extension of the CTV into adjacent bone may  be carved out.  Anatomical boundaries to 
consider if 3DCRT is used include superiorly from L5 -S1 to 0.5 cm below the tip of the urethral 
contrast dye inferiorly to ensure that the entire prostate gland is included (MRI can also be used 
to help define the apex). Lateral borders will be at least 1 cm from the pelvic brim. In the lateral 
fields, the external and internal iliac lymph nodes below the SI joints, and the posterior extension 
of the seminal vesicles should be covered. The usual posterior border is approximately S2 -3, but 
________________________________________________________________________  
22 CT anatomy should take precedence. The inferior extent of the external iliac lymph nodes is at 
the top of the femoral heads. The inferior extent of the obturator lymph nodes is at the top of the 
symphysis pubis.  
 
If there are grossl y involved nodes seen in the pelvis, this can be treated to a higher dose using a 
simultaneous integrated boost technique  (see section 4.4.1.1 and Table 4.4 .1.2).  For these 
patients, a GTV -N will be defined as the grossly evident node based on imaging stu dies (> 1.5 cm 
for solitary, and > 1 cm for multiple nodes at the discretion of treating physician)  (see section 
4.4.1 .5.2.1).  Imaging studies prior to hormone therapy can be used to guide in the delineation of 
GTV-N. Alternatively for node positive patie nts, a CT simulation in the treatment position can be 
performed prior to hormone therapy to be used in fusion with CT simulation to be performed at a 
later date to help define the nodal volume.  CTV -N will be defined as being GTV -N + 7mm margin 
in 3-dimens ions.  As always careful consideration will be made in defining CTV to carve disease 
out of the bowel.   
 
Planning Target Volume  
The PTV1 margins should be a minimum of 0.5 cm and a maximum of 1.5 cm in all dimensions.  
 
4.4.1 .5.2.2 Plan 2 Prostate and Prox imal Seminal Vesicles Boost with IMRT  
Gross Target Volume (GTV 2)  
See Section 4.4.1 .5.2.1 above for GTV1.  
 
Clinical Target Volume (CTV2)  
The CTV2 is the GTV2 plus areas considered to contain microscopic disease, delineated by the 
treating physician. The C TV2 includes the GTV (prostate) plus areas at risk for microscopic 
disease extension plus the proximal bilateral seminal vesicles. Typically, only the proximal 1.0 cm 
of seminal vesicle tissue adjacent to the prostate shall be included in the clinical targ et volume. 
This 1.0 cm of seminal vesicles refers to both radial (in plane) and superior (out of plane) extent. 
If both prostate and seminal vesicle are visualized in the same CT slice, this seminal vesicle 
tissue will contribute to the 1.0 cm of tissue as  seen on the CT simulation scan. For patients with 
clinical biopsy proven involvement of the seminal vesicles, or with imaging evidence of seminal 
vesicle involvement, or with clinical suspicion at the discretion of treating physician, treatment of > 
1 cm of the proximal seminal vesicles (up to entire seminal vesicle), is acceptable as long as it 
does interfere with the ability to achieve dose constraints to the critical normal structures (see 
section 4.4.1 .5.3).  
 
Planning Target Volume (PTV2)  
The PTV2 will  provide a margin around the CTV2 to compensate for the variability of treatment 
set up and internal organ motion. A range of 5 -10 mm around the CTV is required to define each 
respective PTV. Individual selection of a PTV margin should be based on the inst itution’s level of 
confidence in patient set -up and the availability of image guidance. Superior and inferior margins 
(capping) should be 5 -10 mm depending on the thickness and  
spacing of the planning CT scan. Careful consideration should be made when defi ning the 5 - 10 
mm margin in 3 dimensions.  
 
4.4.1 .5.3 Normal Critical Structures and Dose Constraints  
Normal critical structures to be defined on the treatment planning CT scan will include the 
following: bladder, rectum (from its origin at the rectosigmoid  flexure superiorly or the bottom of 
the SI joints, whichever is more inferior to the inferior -most extent of the ischial tuberosities), 
sigmoid colon (to the level of superior border of PTV1),  bilateral femora (to the level of ischial 
tuberosity), penile  bulb, and skin. Any small bowel within the primary beam aperture should be 
defined as well. The normal tissues will be contoured and considered as solid organs. The 
bladder should be contoured from its base to the dome, and the rectum from the anus (at th e 
level of the ischial tuberosities) for a length of 15 cm or to the rectosigmoid flexure. This generally 
is below the bottom of the  sacroiliac joints. If IMRT is being used to treat the pelvic nodes, the 
potential bowel space (not just individual loops of  bowel) where the small and large bowel may 
________________________________________________________________________  
23 fall should be outlined. The borders are the abdominal wall anteriorly, pelvic sidewalls laterally 
(excluding the pelvic lymph node regions), superiorly to one cut above the last axial CT image on 
which the lymph  nodes are outlined and inferiorly from the level of the top of PTV1 (outlining  
around the sides of the bladder near the top of the bladder to encompass the bowel that may fall 
into these regions). See the ITC web site ( http://atc.wustl.edu ) to view exampl es of target and 
normal tissue contours.  
The following table summarizes the dose constraints for the critical structures.  
 
Table 4.4 .3 Organs at Risk, and Dosimetric Constraints  
 
 ≤ 15%  ≤ 20%  ≤ 35%  ≤ 50%  
Rectum/Sigmoid  75 Gy  70 Gy  65 Gy  40 Gy  
 10 cc < 75.6 Gy  
20 cc < 70 Gy  
Bladder  80 Gy  75 Gy  70 Gy  50 Gy  
 90 cc < 70 Gy  
150 cc < 65 Gy  
Potential Bowel 
Space  0.03 cc < 50.4 Gy * 
50 cc < 45 Gy * 
L and R Femur  ≤ 5% receives 50 Gy  
Penile bulb  Mean dose ≤ 52.5 Gy  
 
 
While every effort should be made to deliver prescription doses to the PTV as specified while 
adhering to these constraints, it is recognized that certain anatomical factors may prevent this. 
Prescription dose reduction to  a level of 77.4 Gy or 75.6 Gy is permitted if constraints cannot be 
met at a prescription d ose of 79.2 Gy. For purposes of compliance, up to a 5% absolute increase 
in the volume of critical structure receiving greater than the specified dose will be consi dered 
”variation acceptable,” e.g. up to 20% of the rectum may receive a dose of > 75.6 Gy without a 
protocol deviation. Any increase in critical structure volume greater than 5% receiving more than 
the specified dose will be considered a ”deviation unacce ptable.” It is at this point that a dose 
reduction to 77.4 Gy or 75.6 Gy should be implemented. The prescription dose should be the 
maximum deliverable up to 79.2 Gy while respecting the critical normal structure constraints. Of 
note, the penile bulb const raint is to be regarded as a guideline, and adherence to this should not, 
in any way, result in a reduction of the prescription dose or compromised dose coverage of the 
target volume.  In the event that PTV -N is in close proximity to the small bowel, absol ute small 
bowel constraints will be prioritized over PTV -N coverage. * variation will be noted if > 50 cc to 
150 cc of potential small bowel space receives ≥ 45 Gy. A secondary variation will be noted if > 
150 cc receives >45 Gy. However, at the discretion  of the treating physician, will consider max 
point dose up to 55 Gy.   
 
4.4.1 .6 Treatment Verification  
4.4.1 .6.1  For 3DCRT: First day port films or portal images of each field along with orthogonal 
isocenter verification films (or images) must be obtaine d. If modifications are made in field 
shaping or design, a port film/image of each modified field along with orthogonal isocenter 
verification films (or images) is required on the first day’s treatment of that field. Thereafter, 
weekly verification films o r images of orthogonal isocenter views (anterior to posterior and lateral 
projection) are required.  
 
For IMRT:  the intensity profiles of each beam must be independently verified and compared to 
the planned field intensity. Portal films/images are required  for IMRT but orthogonal verification 
films/images are required, just as for 3DCRT. Real -time ultrasound localization and on -line cone 
beam CT image guidance are important complements to conventional port films or portal imaging 
and should be used when ava ilable. Weekly port filming/imaging is required in this study.  
 
________________________________________________________________________  
24 4.4.1 .6.2 Daily on -line target localization (kV or MV imaging with fiducials, kV or MV ConeBeam 
CT, trans -abdominal ultrasound, or other) or off -line adaptive approaches to account for 
interfr action organ motion and setup  variability are permitted on this study.  Fiducials (gold seeds) 
will be placed by the UT Southwestern Urology department at least 10 -14 days prior to the 
intiation of radiation therapy date  and details for this process are  outlined in  4.4.2 .  Calypso 
Beacons are permitted to be used in place of gold seed fiducial markers, if monitoring 
intrafractional motion is desired at the discretion of the treatment team.  
 
4.4.1 .7 Quality Assurance  
4.4.1 .7.1 Compliance Criteria for Cases T reated with EBRT  
Cases that are treated entirely with external beam radiation therapy must meet the criteria 
as stated in Sections 4.4.1 .1 and 4.4.1 .2 (see also Tables 4.4.1.1, 4.4 .1.2, and 4.4.2). Both the 
Plan 1 and 2  requirements must be met.  In additi on, the critical structure dose  constraints of 
Section 4.4.1 .5.3 and Table 4.4.3 must be met.  
4.4.1 .7.1.1 Acceptable dose heterogeneity for external beam treatment is summarized in Tables 
5.1 and 5.2. The treating physician must carefully consider the tol erance dose/volume to each 
critical normal structure and unspecified tissue.  
4.4.1 .7.2 Radiation Quality Assurance Review  
The study’s radiation PI or his designees will perform an RT Quality Assurance remote review 
after complete data for the first 4 of th e cases enrolled has been made available. The study PI or 
his designees will perform the next remote review after complete data for the next 3 cases have 
been enrolled. The final cases will be reviewed within 3 months after this study has reached the 
targe t accrual or as soon as complete data for all cases enrolled has been made available, 
whichever occurs first. These reviews will be ongoing and performed remotely . 
 
4.4.1 .8. Radiation Therapy Adverse Events  
All patients will be seen weekly by their treatin g radiation oncologist while undergoing EBRT. Any 
observations with respect to the following symptoms/side effects will be recorded:  Bowel/rectal 
irritation manifesting as cramping, diarrhea, urgency, proctitis, or hematochezia, urinary 
frequency, urgency,  dysuria, hematuria, urinary tract infection, or incontinence. CTCAE  4.0 will be 
used to grade all toxicities.  
 
4.4.1 .8.1. Clinical discretion may be used in managing radiotherapy -related side effects. 
Diarrhea/rectal  frequency/urgency may be managed with diphenoxylate or loperamide. Bladder 
irritation may  be mitigated with phenazopyridine. Urinary frequency/urgency can be managed with  
anticholinergic agents or alpha -blockers such as tamulosin.  Erectile dysfunction can be managed 
with phosphodiesterase (PD E) inhibitors such as sildenafil.   
 
4.4.1 .9. Quality of Life Outcomes Related to Radiation Treatment  
All patients will be given quality of life and symptom monitoring questionnaires including AUA 
symptom score sheet  and the SHIM score sheet .  The  questio nnaries will be given at the 
radiation consult visit and at follow up visits as part of the standard of care treatment . 
 
4.4.2  SURGICAL PROCEDURES  
4.4.2.1  Gold fiducial marker placement.  
Gold seeds will be placed under ultrasound guidance in the prostate of patients as fiducial 
markers for radiation therapy prior to commencement of EBRT. Fiducial marker placement is 
standard of care for patients undergoing EBRT and will be performed following standard 
techniques.  
 
4.4.2.2.  Prostate biopsies.  
Standard 12 -core biopsies for diagnosis will be performed under transrectal ultrasound (TRUS) 
guidance at study entry on subjects who have not yet undergone diagnostic biopsy for prostate 
cancer. At the same time, up to 6 additional targeted core biopsy research samples  will be 
obtained for purposes of the correlative studies described in Section 9.0. Subjects who have 
already undergone diagnostic prostate biopsies at the time of screening will undergo repeat 
________________________________________________________________________  
25 TRUS -guided biopsy to obtain up to  6 core biopsy samples for c orrelative studies at the time of 
study enrollment. TRUS -guided biopsy is performed as standard of care for the diagnosis and 
risk-stratification of patients with prostate cancer. A second set of up to -6 targeted research 
biopsy samples will be obtained u nder TRUS -guidance at the time of gold seed fiducial marker 
placement in all subjects enrolled in the study.  
 
Biopsies  will be formed using the Koelis Urostation with  PROMAP -MR software. This approved, 
commercially available imaging a nd biopsy technology p ermits  3-dimensional transrectal 
ultrasound and MRI fusion to target tumor tissue within the prostate for biopsy, and will permit 
repeat biopsy of the same sites. The Urostation is a mobile software platform which can improve 
the prostate biopsy procedure with 3D imaging and image fusion capabilities. The Urostation 
connects to an ultrasound scanner equipped with a 3D transrectal probe. It receives stores and 
processes 3D Dicom images of the prostate as the physician performs the biopsy procedure.  
Organ -Based Tracking is an automatic 3DTRUS/3DTRUS registration based on the organ 
position within the image. This registration is robust to prostate and patient motion.  The 
MRI/3DTRUS fusion is elastic since prostate deformation is corrected for optimal precisio n using 
a morphological contouring method.  One significant advantage of this system is allowing 
mapping of biopsies as the  Urostation guides and records each biopsy.  It also allows real -time 
feedback on the targeted prostate region with an overlay of pri or biopsy locations so a rebiopsy 
can be performed accurately of the region of interest.  
 
4.5 Duration of Therapy  
In the absence of treatment delays due to adverse events, treatment may continue for up 
to 36 months or until:  
 Disease progression  
 Inter-current illness that prevents further administration of treatment  
 Unacceptable adverse event(s)  
 Subject  decides to withdraw from the study, OR 
 General or specific changes in the patient’s condition render the subject  
unacceptable for further treatment in the jud gment of the investigator”.  
4.6 Duration of Follow Up  
Subjects  will be followed for 12 months after initiation of treatment  with enzalutamide 
plus GnRH agonist or until death, whichever occurs first. Subjects removed from 
treatment  for unacceptable adverse eve nts will be followed until resolution or sta bilization 
of the adverse event . Subjects will be followed at monthly (every 28 +/ - 3 days) visits for 
12 months from the time of initiation of treatment with enzalutamide plus GnRH agonist. 
Total treatment will be for up to 36 months.  The frequency of the f ollow up visits will be at 
the discretion of the investigator  up to 36 months. The duration of treatment with the study 
agent enazalutamide will be for the initial 6 months, and follow up on study will continue 
for an additional 6 months following completion of enzalutamide.  
4.7 Removal of Subjects  from Protocol Therapy  
Subjects  will be removed from therapy  when any of the criteria listed in Section 5.5 apply . 
Notify the Principal Investigator, and document the reas on for study removal and the date 
the subject was removed in the Case Report Form . The subject should be followed -up 
per protocol .  
4.8 Subject Replacement  
If a subject is withdrawn from the study prior to the initiation of radiation therapy for 
reasons other than AEs as outlined in tables 4.2.1 and 4.2.2, an additional subject may 
be added to the study.  
________________________________________________________________________  
26 5.0 STUDY PROCEDURES  
5.1 Screening/Baseline Procedures  
Assessments performed exclusively to determine eligibility for this study will be done only 
after obtaining inf ormed consent. Assessments performed for clinical indications (not 
exclusively to determine study eligibility) may be used for baseline values even if the 
studies were done before informed consent was obtained.  
 
All screening procedures   with the exception  of a bone scan, must be performed 
within - 56 days prior to registration unless otherwise stated. A bone scan must be 
performed within – 90 days prior to registration. The screening procedures include:  
5.1.1  Informed Consent  
5.1.2  Medical history  
Complete medical and  surgical history, history of infections  
5.1.3  Demographics  
Age, gender, race, ethnicity  
5.1.4  Review subject eligibility criteria  
5.1.5  Review previous and concomitant medications  
5.1.6  Physical exam including vital signs, height and weight  
Vital signs (temperature, pulse, respi rations, blood p ressure), height, weight  
5.1.7  Performance status  
Performance status evaluated prior to study entry .  
5.1.8  Adverse event assessment  
Baseline adverse events will be assessed. See section 6 for Adverse Event 
monitoring and reporting.  
 
5.1.9  Hematology  
5.1.10  Blood d raw for baseline blood counts, s erum chemistries , PSA, and 
 testosterone : 
Complete blood count with automated or manual differential. Comprehensive 
metabolic panel (CMP) to include: albu min, alkaline phosphatase, ALT/SGPT, 
AST/S GOT, BUN, creatinine, electr olytes (sodium, potassium, calcium, chloride, 
bicarbonate), glucose, and total bilirubin.  PSA. Serum total testosterone.  
5.1.11  Tumor assessment  and imaging  
5.1.12.1  For patients with prostatic adenocarcinoma histologically 
confirmed prostatic adenocarcinoma, ima ging assessment will include CT of the 
abdomen and pelvis OR pelvic MRI; PA/lateral chest x -ray OR chest CT; and 
bone scan. CT, MRI, and CXR must be performed within 56 days of enrollment. 
Bone scan must be performed within 90 days of enrollment. At enroll ment, these 
subjects will undergo a research MRI of the prostate with TRUS -guided targeted 
prostate tumor biopsies. For patients who have not yet undergone CT 
abdomen/pelvis or MRI of the pelvis but are otherwise eligible for the trial, the 
________________________________________________________________________  
27 mandated resear ch sequences from the prostate MRI may be obtained 
concurrently with the required standard of care MRI.  
5.1.12 .2 For subjects who have not yet undergone diagnostic prostate 
biopsies  to confirm the presence of prostatic adenocarcinoma  at the time of study 
enrollment , but who otherwise meet eligibility criteria (as defined in section 3.1.1 : 
serum PSA > 20 ng/dL and/or clinical T3 disease by digital rectal exam ), 
standard of care diagnostic and research biopsies of the prostate will be 
performed simultaneousl y under ultrasound guidance. Subjects will undergo MRI 
of the pelvis, bone scan, and CXR (PA and lateral) or chest CT  at enrollment. MRI 
of the pelvis must be performed prior to prostate biopsy.  
 
  
5.2 Procedures During Treatment  
Subjects will receive treatment  in the following phases:  
o Neo-adjuvant: Subjects will receive treatment with enzalutamide plus GnRH agonist 
for 8-10 weeks prior to the initiation of EBRT  
o Concurrent: Subjects will continue to receive treatment with enzalutamide plus GnRH 
agonist for the duration of EBRT (8 -10 weeks)  
o Adjuvant: Subjects will receive treatment with enzalutamide plus GnRH agonist 
following completion of EBRT until a total duration of 24 weeks of enzalutamide plus 
GnRH agonist treatment has been completed  
o Maintenance: Subjects  will continue to receive GnRH agonist therapy following 
completion of treatment with enzalutamide to achieve a total of 24 - 36 months of 
GnRH agonist treatment.  
o During the neo -adjuvant, concurrent, and adjuvant phases, subjects will receive 
treatment wit h enzalutamide plus GnRH agonist therapy for six 28 day cycles for a 
total duration of 24 weeks.  
5.2.1  Prior to Each Treatment Cycle  During Neo -Adjuvant, Concurrent, and 
Adjuvant phases (weeks 1 -24): 
 Physical exam, vital signs  
 Hematology  
 Serum chemistries  
 Toxici ty evaluation  
5.2.2  Day – 56 to – 14: 
 Procedure:  
o MRI pelvis  
o TRUS -guided prostate biopsies   
5.2.3  Week s 7-11 
 MRI pelvis  
 Fiducial marker placement and TRUS -guided targeted prostate biopsies  
5.2.4  Every 4 weeks during weeks 28 -48 of Maintenance Phase:  
 Physical exam, vital si gns 
 Hematology  
 Chemistries  
 Toxicity evaluation  
5.2.5  Every 8 weeks during weeks 1 -48:  
 PSA, testosterone  
________________________________________________________________________  
28 5.3 Follow -up Procedures  
Subjects  will be followed every 4 weeks (+/- 3 days)  after com pletion of (or early 
withdrawal from) study treatment until 48 weeks (12 m onths) after initiation of 
enzalutamide plus GnRH agonist . Following completion of the study, subjects will 
continue with maintenance therapy with GnRH agonist for up to 36 months total 
treatment time as standard of care and will be monitored at the discre tion of the treating 
provider according to standard of care.  
5.4 Time and Events Table  
 
  Pre-study  
Days -56 
to - 14 Day 1  Every 4 
weeks 
(weeks 4-
48)  Every 8  
Weeks  
(weeks 
8-48) Weeks 8 -
10 End of 
study visit  
Assessment        
Informed Consent  X      
History  and PE  X X X   X 
Performance 
Status  X X X   X 
Toxicity 
Evaluations   X X   X 
CBC  X X* X    
CMP  X X* X    
PSA, 
testosterone  X X*  X   
       
       
CXR PA/lateral  or 
CT chest  X      
Bone scan  X#      
CT abd and 
pelvis  x      
MRI pelvis  X    X  
TRUS -guided 
prostate biopsy  X    X  
 *These tests will be repeated at day 1 if the pre -screening tests were done greater than 28 days 
before Day 1 . 
 
# Bone scan will be performed during pre -study days – 90 to – 14. 
5.5 Removal of Subjects from Study  
Subjects  can be taken off the study treatment and/or study at any time at their own 
request, or they may be withdrawn at the discretion of the investigator for safety, 
behavioral or administrative reasons. The reason(s) for discontinuation will be 
documented and ma y include:  
5.5.1  Subject  voluntarily withdraws from treatment (follow -up permitted);  
5.5.2  Subject  withdraws consent (termination of treatment and follow -up); 
5.5.3  Subject  is unable to comply with protocol requirements;  
5.5.4  Subject demonstrates disease progression (unless continued treatment with 
study drug is deemed appropriate at the discretion of the investigator);  
________________________________________________________________________  
29 5.5.5  Subject  experiences toxicity that makes continuation in the protocol unsafe;  
5.5.6  Treating physician judges continuation on the stu dy would not be in the subject’s 
best interest;  
5.5.8  Development of second malignancy (except for basal cell carcinoma or 
squamous cell carcinoma of the skin) that requires treatment , which would 
interfere with this study;  
5.5.9  Lost to follow -up. If a re search subject canno t be located to document surviv al 
after a period of 12 months , the subject may be considered “lost to follow -up.” All 
attempts to contact the subject during the 12 months  must be documented and 
approved by the Data Monitoring Committee.  
6.0 Measurement of Effect  
6.1 Antitumor Effect - Solid Tumors  
 
Patients with high -risk localized or locally -advanced prostate cancer are eligible for 
enrollment in this study. Patients with high -risk localized prostate cancer by definition will 
not have measurable  disease by RECIST. Patients also may have radiographic evidence 
of metastasis in regional lymph nodes (N1 disease as defined by the National 
Comprehensive Cancer Network Prostate Cancer Guideline Verson 3.2012) at the 
discretion of the treating physicians , if regional lymph nodes can be included in the 
planned radiation field. RECIST will not be used to monitor these regional lymph nodes 
for treatment response. Rather, in all patients, treatment response will be monitored by 
serum prostate specific antigen  (PSA). The PSA nadir with EBRT combined with 
androgen deprivation therapy is known to vary. Following RTOG -ASTRO Phoenix 
Consensus, a PSA rise by 2 ng/mL or mor e above the nadir PSA is the standard 
definition for biochemical failure after EBRT with or wit hout ADT. As the primary endpoint 
of this study is safety and tolerability as measured up to 12 months following initiation of 
combined enzalutamide and GnRH agonist therapy, it is expected that subjects will 
remain under treatment with maintenance GnRH ag onist therapy at the completion of 
their time on study. Consequently, it is anticipated that subjects will not experience a PSA 
rise suggestive of disease progression as defined by RTOG -ASTRO Phoenix Consensus 
during the study enrollment period. Should sub jects experience any PSA rise on 2 or 
more consecutive measurements while enrolled in the study, this will be considered 
evidence of disease progression. Subjects will undergo research MRI of the pelvis to 
quantify local response following 8 weeks of combi ned enzalutamide plus GnRH agonist 
treatment for research purposes.  
 
6.1.1  Definitions  
Evaluable for toxicity . All subjects  will be evaluable for toxicity from the time of 
their first treatment with study drug.  
 
6.1.2  Methods for Evaluation of Measurable Disease : Magnetic Resonance 
Imaging ( MRI) of the prostate and pelvis  
6.1.2.1  Patient preparation  
The participants will undergo prostate MRI following the standard institutional 
procedure. If patients have had prostate biopsies, a minimum of 3 weeks is 
recommended betw een the date of the MRI exam and the previous biopsy to 
reduce the influence of post -biopsy changes in diagnostic accuracy.15 Patients 
will be asked to refrain from ejaculation for 3 days preceding the examination to 
maximize distention of the seminal vesicle.16 
________________________________________________________________________  
30  
6.1.2.2  Image acqu isition  
Patients will undergo an MR examination with our routine clinical protocol using a 
3T MRI system (Philips Medical Systems, Cleveland, OH) and a pelvic phased -
array coil. Endorectal coil will not be used. The patient is imaged in the supine 
position  and artifacts due to bowel peristalsis are minimized with sublingual 
administration of 0.250 mg of hyoscyamine sulfate (Levsin). Our protocol 
includes T2 -weighted fast spin -echo images in the transverse, sagittal, and 
coronal planes; axial diffusion -weigh ted transverse single shot echo planar image 
(with ADC map); T1 -weighted gradient -echo images acquired before, during, and 
following the intravenous injection of a single dose of a gadolinium -based 
contrast as it is done for our clinical prostate MRI proto col. Additional pulse 
sequences such as arterial spin labeling (ASL), blood oxygen level dependent 
(BOLD), and others might be incorporated into the MRI protocol for additional 
research purposes; the total examination time will not exceed 1.5 hours and the  
amount of intravenous contrast administered will be similar to the dose given for 
clinical prostate MRI examinations. If at any point during the study the participant 
indicates a desire to withdraw, the exam will be interrupted.  
 
6.1.2.3  Potential risks  associated with MRI  
Patients will be screened for MRI contraindications and these will be exclusion 
criteria for this study. Safety rules will be strictly enforced and followed by the 
research study team, MRI technologists, and the study subjects themselves . 
During the MRI scanning process, the study team is in constant two -way 
communication with the participant and can remove him from the magnet 
immediately as needed. The MRI personnel are trained to respond to emergency 
situations, further supported by an institutional Rapid Response Team should an 
adverse event arise during the study visit. Standard radiofrequency coils 
provided by manufacturers of MRI machines will be used in this study. The risks 
associated with the use of these coils are minimal.  Howev er, with any RF coil, 
there is a small risk of skin burns if the coil is used improperly or is 
malfunctioning.  The MRI staff at UT Southwestern Medical Center is fully trained 
in the proper use of these devices.  
 
Subjects will be screened for renal impair ment prior to administration of 
gadolinium -based contrast agents as it is routinely done in the Radiology 
Department at UT Southwestern. A serum creatinine determination within 30 
days prior to the research MRI examination must be available to calculate an  
estimated glomerular filtration  rate (eGFR). An eGFR calculation may be 
repeated closer to the MRI appointment if the patient’s medical condition has 
changed. An eGFR ≥45 mL/min/1.73m2 is considered acceptable for 
administration of a standard weight -based dose of intravenous contrast fo r 
research purposes.17  
 
We do not anticipate significant psychologic al stress related to this study 
procedure .  Patients will be able to refuse to answer any of the  questions, take a 
break or stop their participation in this study at any time.  
 
6.1.2.4  Image interpretation  
MR images will be interpreted by a sin gle radiologist . The following criteria for 
tumor identification are widely accepted in the literature and a re used in routine 
clinical practice: round or ill -defined, low -signal -intensity focus in the peripheral 
zone; or homogeneous signal mass with indistinct margins in the transition zone 
on T2 -weighted imaging; high signal intensity on DWI and low ADC values  when 
compared to the remainder of the prostate tissue.18 In addition, dynamic contrast -
enhanced images will be analyzed using a FDA -approv ed software for 
________________________________________________________________________  
31 pharmacokinetic evaluation (VividLook with Versavue Enterprise, iCAD, Nashua, 
NH). Suspicious areas for tumor are defined as those with increased relative 
peak enhancement and subsequent decrease in signal intensity —“rapid wash -in 
and wash -out pattern”). Color -coded map will be generated to highlight areas 
with high microvascular permeability and low to medium extracellular volume 
fraction.19  
 
6.1.2.5  MRI-US image fusion  
Anatomic co -registration of biopsy samples and MRI findings are essential in this 
proposal. Transrectal ultrasound images will be fused with initial MRI performed 
prior to therapy us ing a specialized device (UroStation; Koelis , Grenoble, 
France). This technology allows 3 -dimensional anatomic co -registration of 
volumetric transrectal ultrasound (TRUS) and MRI acquisitions. Once the TRUS 
and MRI volumes are co -registered, the urologist can use the real -time fusion 
dataset to perform routine sextant biopsies and also target biopsies directly to the 
suspicious areas on MRI. Furthermore, this system allows for saving a 3D map of 
the prostate with the biopsy tracts of the needle biopsies and  data from 
pathologic analysis, once it becomes available, can be loaded into the system for 
further analysis. Because these 3D maps can be loaded into the biopsy US unit 
prior to performing the follow -up biopsy after treatment, we will use this capability  
to facilitate the anatomic coregistration of the initial pre -treatment biopsies and 
the repeat biopsy perform ed after treatment .20  
 
6.1.2.6  Evaluation of changes in tumor volume and tumor activity  
Tumor volume will be assessed using a planimetric approach.21 On each MRI 
prostate section the outline of suspicious areas will be traced on the computer 
screen and the surface area will be calculated. After counting the number of 
separate foci and defining the most representative site of origin, tumor foci 
volume  will be calculated by multiplying the sum of the suspicious surface areas 
by the slice thickness (usually 2 -3 mm).  
 
Tumor activity will be assessed using apparent diffusion coefficient (ADC) 
derived from diffusion -weighted imaging, which has been shown to  correlate with 
Gleason score and percentage of tumor on core biopsy (as surrogates for tumor 
aggressiveness).22,23 ADC values will be derived by drawing a region of interest 
on the confirmed tumors, and expressed as mean values and histograms.  
6.2 Safety/tolerability  
  Analyses will be performed for all subjects  having received at least one dose of study 
drug. The s tudy will use the CTCAE version 4.0 for reporting of non -hematologic adverse 
events ( http://ctep.cancer.gov/reporting/ctc.html ) and modified criteria for hematologic 
adverse events . 
7.0 ADVERSE EVENTS  
7.1 Experimental Th erapy  
For the most recent safety update, please refer to the current Investigator’s Brochure or 
Study Agent Prescribing Information . 
7.1.1  Contraindications : Enzalutamide is contraindicated in pregnancy.  
7.1.2  Special Warnings and Precautions for Use : Seizure occurred  in 0.9% of patients 
who received enzalutamide in a completed phase III trial. There is no clinical trial experience with 
enzalutamide in patients who have had a seizure, in patients with predisposing risk factors for 
________________________________________________________________________  
32 seizure, or in patients using concomit ant medications that may lower the seizure threshold. 
Patients with a history of seizure or with predisposing risk factors for seizure are ineligible to 
participate in this study.  
7.1.3  Interaction with other medications :  
In vitro studies show that enzalutamide  and/or metabolite M2 are potential inhibitors of  
CYP2C8 and CYP2C19 with lesser potential for inhibitory effects on CYP2B6 and 
CYP2C9. Enzalutamide is a moderate CYP2C9 and CYP2C19 inducer in humans. For 
this study, s ubstrates of CYP2B6, CYP2C8, CYP2C9, a nd CYP2C19 that have a narrow 
therapeutic index (e.g., paclitaxel, phenytoin, warfarin, omeprazole) are prohibited  during 
the period of enzalutamide administration .  
 
In vitro studies show that enzalutamide is an inducer of CYP3A4. Induction of CYP3A 
occur s via activation of the nuclear pregnane X receptor (PXR), which is expected to 
result in co -induction of CYP2C. Co -administration of enzalutamide with CYP3A or 
CYP2C substrates may reduce oral bioavailability and/or accelerate elimination of these 
substra tes. Enzalutamide is a strong CYP3A4 inducer in humans. For this study, narrow 
therapeutic index drugs that are metabolized by CYP3A4 (e.g., alfentanil, cyclosporine, 
dihydroergotamine, ergotamine, fentanyl, pimozide, quinidi ne, sirolimus and tacrolimus) 
are prohibited.  
 
In vitro studies show that enzalutamide is metabolized by CYP2C8 and CYP3A4/5. 
Strong inhibitors or inducers of these enzymes may affect enzalutamide exposures. Co -
administration of a strong CYP2C8 inhibitor (gemfibrozil) increased the comp osite area 
under the plasma concentration -time curve (AUC) of enzalutamide plus N -desmethyl 
enzal utamide in healthy volunteers. For this study, c o-administration of enzalutamide and 
strong CYP2C8 inhibitors (e.g., gemfibrozil) is prohibited. Co -administrat ion of a strong 
CYP3A4 inhibitor (itraconazole) increased the composite AUC of enzalutamide plus N -
desmethyl enzalutamide by 1 .3 fold in healthy volunteers. For this study, co -
administration of enzalutamide and s trong inhibitors of CYP3A4/5 (e.g., clarithr omycin, 
itraconazole, ketoconazole) are prohibited.  
 
Use caution when co -administering strong inducers of CYP2C8 (e.g., rifampin) or  
CYP3A4/5 (e.g., carbamazepine, phenytoin, rifampin, St. John’s wort) during 
enzalutamide treatment, as enzalutamide concent rations may decrease.  
 
In vitro studies show that enzalutamide and metabolite M2 are potential inhibitors of the 
efflux transporter P -gp. Co -administration of enzalutamide with P -gp substrates may 
increase the plasma concentrations of the P -gp substrate. U se caution when co -
administering sensitive P -gp substrates (e.g., colchicine, dabigatran etexilate, digoxin) 
during enzalutamide treatment.  
 
7.1.4  Adverse Reactions  
 The most common adverse reactions ( >5%) reported in patients receiving enzalutamide 
in the compl eted randomized clinical trial, which included patients with metastatic castrate -
resistant prostate cancer who previously received docetaxel chemotherapy, included 
asthenia/fatigue, back pain, diarrhea, arthralgia, hot flush, peripheral edema, musculoskele tal 
pain, headache, upper respiratory infection, muscular weakness, dizziness, insomnia, lower 
respiratory infection, spinal cord compression and cauda equine syndrome, hematuria, 
paresthesia, anxiety, and hypertension. Grade 3 and higher adverse reactions  were reported 
among 47% of enzalutamide -treated patient and 53% of placebo -treated patients.  
 
PRES is a rare, reversible, neurological disorder which can present with rapidly evolving 
symptoms including seizure, headache, confusion, blindness, and other v isual and neurological 
________________________________________________________________________  
33 disturbances, with or without associated hypertension. A diagnosis of PRES requires confirmation 
by brain imaging, preferably magnetic resonance imaging (MRI). Discontinuation of enzalutamide 
in patients who develop PRES is recommend ed. Patients should be informed to contact the study 
physician as soon as possible if they experience rapidly worsening symptoms possibly indicative 
of PRES such as seizure, headache, confusion, reduced eye sight, or blurred vision.  
Three reported PRES cas es include one clinical trial case assessed as unrelated to enzalutamide 
treatment and two post -marketing cases assessed as possibly associated with enzalutamide. 
One confirmed case of PRES, assessed as unrelated to enzalutamide, was reported in Study S -
3100-1-01 (first in man dose escalation study in castration -resistant prostate cancer patients). 
The onset of PRES symptoms occurred approximately 27 days after discontinuation of 
enzalutamide, and approximately 19 days after initiating treatment with an inv estigational insulin -
like growth factor (IGF) antibody (onset - 3 days after the second dose). PRES was likely 
associated with the investigational IGF antibody based on temporal relationship and positive 
dechallenge.  
Two post marketing cases of confirmed P RES were identified from the global safety database 
(estimated cumulative post marketing exposure of 17,704 patient treatment years as of 
30August2014). In the first case, reported symptoms (confusional syndrome and aphasia; 
symptom onset on treatment day 27) and MRI findings were consistent with a diagnosis of PRES. 
PRES was assessed as possibly associated with enzalutamide treatment in this case based on a 
plausible temporal relationship and the lack of an alternative etiology. The patient received acute 
treatment with intravenous corticosteroids. After discontinuing enzalutamide, reported symptoms 
resolved and a follow -up cerebral MRI revealed regression of abnormalities, indicative of positive 
dechallenge. In the second case, reported symptoms (altered m ental status, confusion, and word -
finding difficulties; with a blood pressure of 188/97 mm Hg; symptom onset on treatment day 98) 
and MRI findings were consistent with a diagnosis of PRES. PRES was assessed as possibly 
associated with enzalutamide treatmen t in this case based on a plausible temporal relationship 
and the lack of an alternative etiology. The patient was treated with dexamethasone and an 
antihypertensive regimen of hydralazine and carvedilol. After discontinuing enzalutamide, 
reported symptoms  resolved and follow -up cerebral MRI finding showed significant improvement, 
indicative of positive dechallenge.  
7.2 Adverse Event Monitoring  
Adverse event data collection and reporting, which are required as part of every clinical 
trial, are done to ensure th e safety of subjects enrolled in the studies as well as those 
who will enroll in future studies using similar agents . Adverse events are reported in a 
routine manner at scheduled times during a trial . Additionally, certain adverse events 
must be reported i n an expedited manner to allow for optimal monitoring of subject safety 
and care .  
 
All subjects  experiencing an adverse event, regardless of its relationship to study drug, 
will be monitored until:  
 the adverse event resolves or the symptoms or signs that  constitute the adverse 
event return to baseline;  
 any abnormal laboratory values have returned to baseline;  
 there is a satisfactory explanation other than the study drug for the changes 
observed; or  
 death.  
7.3 Definitions  
7.3.1  Definition of Adverse Event  
An adver se event (AE) is any untoward medical occurrence in a subject  receiving 
study treatment and which does not necessarily have a causal relationship with 
this treatment. An AE can therefore be any unfavorable and unintended sign 
________________________________________________________________________  
34 (including an abnormal laborat ory finding), symptom, or disease temporally 
associated with the use of an experimental intervention, whether or not related to 
the intervention.  
7.3.2  Severity of Adverse Events  
 
All non -hematologic adverse events will be graded according to the NCI 
Common Ter minology Criteria for Adverse Events (CTCAE) version 4.0. The 
CTCAE v4 is available at http://ctep.cancer.gov/reporting/ctc.html  
 
If no CTCAE grading is available, the severity of an AE is graded as  follows:  
Mild (grade 1):  the event causes discomfort without disruption of normal daily 
activities.  
Moderate (grade 2):  the event causes discomfort that affects normal daily 
activities.  
Severe (grade 3):  the event makes the patient unable to perform norma l daily 
activities or significantly affects his/her clinical status.  
Life-threatening (grade 4):  the subject  was at risk of death at the time of the 
event.  
Fatal (grade 5):  the event caused death.  
7.3.3  Serious Adverse Events  
A “serious” adverse event is defined  in regulatory terminology as any untoward 
medical occurrence that:  
Results in death.  
If death results from (progression of) the disease, the disease  should 
be reported as event (SAE) itself.  
Is life -threatening.  
(the subject  was at risk of death at the ti me of the event; it does not 
refer to an event that hypothetically might have caused death if it were 
more severe).  
Requires in -patient hospitalization or prolongation of existing 
hospitalization  for ≥ 24 hours . 
Results in persistent or significant disability or incapacity.  
Is a congenital anomaly/birth defect  
Is an important medical event  
Any event that does not meet the above criteria, but that in the 
judgment of the investigator jeopardizes the  subject , may be 
considered for reporting as a serious adverse event . The event may 
require medical or surgical intervention to prevent one of the 
outcomes listed in the definition of “Serious Adverse Event“.  
For example: allergic bronchospasm requiring i ntensive treatment in 
an emergency room or at home; convulsions that may not result in 
hospitalization; development of drug abuse or drug dependency.  
 
________________________________________________________________________  
35 7.3.4  Unanticipated Problems:  
The term “unanticipated problem” is found, but not defined in the regulations for  the 
Protection of Human Subjects at 45 CFR 46, and the FDA regulations at 21 CFR 56. 
Guidance from the regulatory agencies considers unanticipated problems to include any 
incident, experience, or outcome that meets each  of the following criteria:  
 unexpect ed; and 
 related  or possibly related  to participation in the research; and 
 suggests that the research places subjects or others at a greater risk of harm  
(including physical, psychological, economic, or social harm) than was previously known 
or recognized.  
 
Follow -up  
All adverse events will be followed up according to good medical practices.  
  
7.3.5  Reporting  
Local events requiring expedited reporting, are submitted to the UTSW IRB through the 
UTSW eIRB and to the SCC DSMC Coordinator.  Hardcopies or electronic versions of 
the eIRB report; the NCI ADEERS, FDA Form #3500A forms, or other sponsor forms, if 
applicable; and/or any other supporting documentation available should be forwarded to 
the DSMC Coordinator.  The DSMC Coordinator forwards the information onto the DSMC 
Chairman who determines if immediate action is required.  Follow -up eIRB reports, and 
all subsequent SAE documentation that is available are also submitted to the DSMC 
Chair who determines if further action is required.    
  
The DSMC Chairperson r eviews all serious adverse events within upon receipt from the 
DSMC Coordinator.  The DSMC Chairperson determines whether action is required and 
either takes action immediately, convenes a special DSMC session (physical or 
electronic), or defers the action  until a regularly scheduled DSMC meeting.  
  
Telephone reports to:  
Kevin Courtney, MD, PhD at 214 -648-4180 or Allison Beaver, RN at 214 -645-8787  
 
UTSW SCC Data Safety Monitoring Committee Coordinator (if fax report is not 
available) within 1 working day t o 214 -648-7097.  
 
Written reports to:  
Kevin Courtney, MD, PhD, or Allison Beaver, RN at 214 -645-8766  
 
UTSW SCC Data Safety Monitoring Committee Coordinator  
Email: SCCDSMC@utsouthwestern.edu  
Fax: 214 -648-7018 or deliver to NB 2.418  
 
UTSW Institutional Review Board (IRB)  
Submit via eIRB with a copy of the final sponsor report as attached supporting 
documentation  
 
1. Unexpected Adverse Events  
Non-serious adverse events which are classified as both unexpected (in terms of nature, 
severity and frequency) and possibly related require reporting to the UTSW IRB within 10 
working days of PI awareness.  
________________________________________________________________________  
36 2. SAEs  
i. Local unanticipated problems require expedited reporting, and are submitted to 
the UTSW IRB through the UTSW eIRB and to the SCC DSMC Coordinator.  
Hardcopies or electronic versions of the eIRB report; FDA Form #3500A forms, 
or other sponsor forms, if applicable; and/or any other supporting documentation 
available should be forwarded to the DSMC Coordinator.  The DSMC  
Coordinator forwards the information onto the DSMC Chairman who determines 
if immediate action is required.  Follow -up eIRB reports, and all subsequent SAE 
documentation that is available are also submitted to the DSMC Chair who 
determines if further acti on is required.    
 
ii. All local serious adverse events which occur on research subjects on protocols 
for which the SCC is the DSMC of record require reporting to the DSMC 
regardless of whether IRB reporting is required. Hardcopies or electronic 
versions of t he FDA Form #3500A forms, or other sponsor forms, if applicable; 
and/or any other supporting documentation available should be forwarded to the 
DSMC Coordinator.   
 
iii. If the event occurs on a multi -institutional clinical trial coordinated by the Cancer 
Cente r, the DOT Manager or lead coordinator ensures that all participating sites 
are notified of the event and resulting action, according to FDA guidance for 
expedited reporting. DSMC Chairperson reviews all serious adverse events 
within upon receipt from the DSMC Coordinator.  The DSMC Chairperson 
determines whether action is required and either takes action immediately, 
convenes a special DSMC session (physical or electronic), or defers the action 
until a regularly scheduled DSMC meeting.  
 
 
Telephone reports  to: 
Kevin Courtney, MD, PhD at 214 -648-4180 or Allison Beaver at 214 -645-8787  
 
UTSW SCC Data Safety Monitoring Committee Coordinator (if fax report is not 
available) within 1 working day to 214 -648-7097.  
 
Written reports to:  
Fax – Kevin Courtney, MD, PhD  or Allison Beaver, RN at 214 -645-8766.  
 
UTSW SCC Data Safety Monitoring Committee Coordinator  
Email: SCCDSMC@utsouthwestern.edu  
Fax: 214 -648-7018 or deliver to NB 2.418  
 
UTSW Institutional Review Board (IR B) 
Submit via eIRB with a copy of the final sponsor report as attached supporting 
documentation  
 
 
3. Unanticipated Problems  
Unanticipated problems, including those that occur as non -local events, require reporting 
to the UTSW IRB within 10 working days of P I awareness of the event.  
For further guidance for Investigators regarding safety reporting requirements for INDs 
and BA/BE studies, refer to FDA Draft Guidance document: 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidan
ces/UCM227351.pdf  
 
________________________________________________________________________  
37 7.4 Steps to Determine If an Adverse Event Requires Expedited Reporting  
Step 1 : Identify the type of adverse event using the NCI C ommon Terminology Criteria 
for Adverse Events (CTCAE v4) .  
 
Step 2 : Grade the adverse event using the NCI CTCAE v4.  
 
Step 3 :Determine whether the adverse event is related to the protocol therapy  
Attribution categories are as follows:  
- Definite – The AE is clearly related  to the study treatment.  
- Probable – The AE is likely related to the study treatment.  
- Possible – The AE may be related  to the study treatment.  
- Unrelated – The AE is clearly NOT related  to the study treatment.  
Note :This includes all events tha t occur within 30 days of the last dose of protocol 
treatment . Any event that occurs more than 30 days after the last dose of treatment and 
is attributed (possibly, probably, or definitely) to the agent(s) must also be reported 
accordingly.  
 
Step 4 : Determ ine the prior experience of the adverse event .  
Expected events are those that have been previously identified as resulting from 
administration of the agent . An adverse event is considered unexpected, for expedited 
reporting purposes only, when either the type of event or the severity of the event is not 
listed in:  
 the current known adverse events listed in the Agent Information Section of this 
protocol;  
 the drug package insert;  
 the current Investigator’s Brochure  
7.5 Reporting Requirements for Adverse Events  
 
 The FDA should be notified within 7 business days of any unexpected fatal 
or life -threatening adverse event with possible relationship to study drug, 
and 15 business days of any event that is considered: 1) serious, 2) 
unexpected, and 3) at least possibly related to study participation.  
 
INSERT PROPER REPORTING PROCEDURES REQUIRED BY SPONSOR   
 Please email or fax the SAE Worksheet to:  
 Astellas Pharma Global Development – United States  
 Email: Safety -us@us.astellas.com  
 Fax number: (847) 317 -1241  
 Follow -up inf ormation for the event should be sent promptly (within 7 days) as 
necessary.  
 Full details of the SAE should also be recorded on the medical records and on 
the CRF.  
 The following minimum information is required:  
 ISN/Study number  
 Subject number, sex and age  
 The date of report  
________________________________________________________________________  
38  A description of the SAE (event, seriousness of the event)  
 Causal relationship to the study drug  
 The period for SAE reporting after the last intake of the study drug should be 
specified.  
 Expedited Safety Reports: An unexpected adverse e vent is one for which the 
nature or severity is not consistent with the current Investigator’s Brochure. The 
Sponsor will make this assessment for all reported serious adverse events. An 
adverse event which is serious, related, and unexpected may be termed  a 
Suspected Unexpected Serious Adverse Reaction (SUSAR). The Investigator will 
ensure that all relevant information is provided as soon as possible to Astellas in 
order that the Sponsor may meet their obligations to report any SUSAR.  
7.5.1  Routine Reporting  
 All other adverse events - such as those that are expected, or are unlikely or 
definitely not related to the study participation - are to be reported annually 
as part of regular data submission.  
7.6 Unblinding Procedures  
This is an open -label study. Unblinding pro cedures will not be applicable.  
7.7 Stopping Rules  
Based on experience from a completed phase III study, enzatlutamide is generally well 
tolerated when given in combination with a GnRH agonist. The most prominent safety 
concerns are primarily related to the ri sk of seizures. No completed study has examined 
the combination of enzalutamide with a GnRH agonist and concurrent radiation. The 
general tolerability of this combination is anticipated to be similar to that of radiation with 
concurrent GnRH agonist therap y. However, the absence of unexpected adverse events 
must be verified and is the primary endpoint of this study. Adverse events will be 
measured by NCI CTCAE criteria and will be monitored and recorded for a period of 12 
months from initiation of the combi nation of enzalutamide plus GnRH agonist. Enrollment 
in the trial will be halted if unacceptable levels of toxicity are found as defined by 3 or 
more patients withdrawing from the study due to AEs.   
8.0 DRUG INFORMATION  
8.1 Enzalutamide  
 Other names for the drug : Xtandi, MDV3100  
 
 Classification - type of agent:  oral androgen receptor inhibitor  
 
 Mode of action:  inhibits androgen -induced receptor activation (binding of androgens 
to ARs in the cytosol), inhibits nuclear translocation of activated ARs, and inhibits the 
association of the activated AR with chromatin  
 
 Storage and stability:  Enzalutamide capsules should be stored at 20 C to 25 C (68 F 
to 77 F) in a dry place. Excursions are permitted from 15 C to 30 C (59 F to 86 F).  
 
 Protocol dose: Subjects will take four 40 mg capsules (160 mg) daily.   Patients will be 
given one bottle of 120 capsules at every 4 week follow up visit. 
 
 Route of administration for this study:  oral 
 
________________________________________________________________________  
39  Availability : provided by sponsor free of charge   
 
 Side effects: Adverse events associated wit h enzalutamide that are most likely to 
occur in this study include asthenia/fatigue, back pain, diarrhea, arthralgia, hot flush, 
peripheral edema, musculoskeletal pain, headache, upper respiratory infection, 
muscular weakness, dizziness, insomnia, lower re spiratory infection, hematuria, 
paresthesia, anxiety, and hypertension. Please refer to the Xtandi (enzalutamide)  
package insert for a comprehensive list of adverse events.  
 
 Nursing implications:  
 
8.2 GnRH agonist  – For the purposes of this study we are only u sing Lupron.  
Additonal GnRH agonists are listed below for informational purposes only.  
 Description: GnRH  agonists are long -acting analogs of the native GnRH peptide and are  
effective at reducing serum testosterone. Analogs approved by the FDA.  
 Supply: Com mercially available.  
 Storage: GnRH analogs should be stored as directed by the commercial supplier.  
 Administration: GnRH analogs are administered with a variety of techniques, including  
subcutaneous insertion of a solid plug in the abdominal wall (Zoladex) , intramuscular injection  
(Lupron), subcutaneous injection (Eligard), or insertion of a long -acting cylinder that slowly  
Releases the agent (Viadur). The manufacturer’s instructions should be followed.  
 Toxicity: Consult the package insert for comprehensive  toxicity information. Class -related  
toxicity is generally a manifestation of the mechanism of action and due to low testosterone  
levels. In the majority of patients testosterone levels increased above baseline during the first  
week, declining thereafter t o baseline levels or below by the end of the second week of  
treatment. The most common side effect of GnRH analogs is vasomotor hot flashes; edema,  
gynecomastia, bone pain, thrombosis, and gastrointestinal disturbances have occurred.  
Potential exacerbation s of signs and symptoms during the first few weeks of treatment is a  
concern in patients with vertebral metastases and/or urinary obstruction or hematuria which, 
if aggravated, may lead to neurological problems such as temporary weakness and/or  
paresthesia  of the lower limbs or worsening of urinary symptoms. Other side effects include  
impotence and loss of libido, weight gain, depression, dizziness, loss of bone density, 
anemia,increased thirst and urination, unusual taste in the mouth, skin redness or hive s, pain 
at injection site, and muscle mass and strength loss, hair changes, penile length and 
testicular volume loss, increased cholesterol, hypertension, diabetes exacerbation, emotional 
lability,nausea, vomiting, and rarely allergic generalized rash and difficulty breathing.  
8.2.1  Return and Retention of Study Drug  
Unused study drug (enzalutamide) will be documented and returned to the 
Simmons Comprehensive Cancer Center Pharmacy for destruction  per Standard 
Operating Procedures  
 
8.2.2 Subject compliance with the study agent, enzalutamide, will be monitored 
through use of a pill diary provided to each subject enrolled in the study. A new 
pill diary will be provided at every 4 week follow up visit for the duration of the 
administration of enzalutamide on the stu dy.  
9.0 CORRELATIVES/SPECIAL STUDIES  
 
The goal of the planned labor atory correlative studies is to  evaluate the proposed mechanism of 
action of enzalutamide  plus GnRH agonist  on patient tumor samples.  The proposed mechanism 
of action of enzalutamide has been established in pre -clinical studies. However, to date the 
molecular mechanism of action has not been reported in primary prostate cancer tumors from 
________________________________________________________________________  
40 patients. The purpose of the proposed laboratory correlative studies is to examine androgen 
signaling inhib ition by enzalutamide in primary tumor samples from patients.  Submission of 
samples for correlative studies is mandatory for participation in this trial.  
9.1 Sample Collection Guidelines  
Up to 6 needle core biopsies will be collected using 18 gauge needles und er TRUS -
guidance at each of two occasions as described in Section 4.4.2.2. Biopsies will be 
performed at study entry and following 8 weeks of treatment with combined enzalutamide 
plus GnRH agonist. Samples will be submitted to pathology laboratory for diag nosis and 
to UTSW tissue bank.  Samples will be labeled with the subject’s de -identified study 
number and collection date and delivered for analysis to:  
Dr. Nima Sharifi, MD  
Cleveland Clinic  and also to Dr. Payal Kapur and Dr. Yi Yin  at UT Southwestern 
Medical Center.  
 
9.2 Assay Methodology  
9.2.1  Immunohistochemistry for Androgen receptor (AR) and Ki -67 will be done using 
routine immunohistochemical assay in a CLIA certified clinical laboratory at UTSW. The 
slides will be analysed under a light microscope to ac cess cellular localization of the 
antibody. Tissue procured for diagnosis will be processed using routine tissue processing 
protocols followed for pathologic diagnosis.  
 
 9.2.2  Gene expression studies  
Ligand -bound androgen receptor (AR) activity may be de fined by the expression of 
androgen -responsive genes.  PSA, TMPRSS2  and FKBP5  are among the most widely 
studied and validated among these genes.24  RNA will be  extracted from the collected 
prostate cancer tissue using the RNeasy system (Qiagen, Germantown, MD), and 1 μg 
RNA will be used in a reverse transcription reaction using the iScript cDNA Synthesis Kit 
(Bio-Rad, Hercules, CA).  Quantitative -PCR (qPCR) anal ysis will be performed in 
triplicate using previously published primers for PSA, TMPRSS2, FKBP5  and for the 
housekeeping gene large ribosomal protein P0 (RPLP0 ).25  Absolute qPCR SYBR Low 
Rox Mix (Fisher, Waltham, MA) will be used in 25 μl final reaction volume, in 96 -well 
plates.  The thermocycling reaction will carried out in an ABI 7500 Real Time PCR 
machine (Applied Biosystems, Foster City, CA).  Accurate quantit ation of each mRNA will 
be achieved by normalizing the sample values to RPLP0  and to vehicle treated cells.  
Samples will be labeled with the subject’s de -identified study number and collection date 
and delivered for gene expression analysis to  
 
Nima Shari fi, M.D.  
Kendrick Family Endowed Chair for Prostate Cancer Research  
Cleveland Clinic  
Lerner Research Institute  
Cancer Biology, NB40  
9500 Euclid Avenue  
Cleveland, OH 44195  
 
 9.2.3  Genomic sequence analysis of selected steroidogenic enzymes  
The first and rat e-limiting step for metabolic flux from adrenal dehydroepiandrosterone 
(DHEA) to dihydrotestosterone (DHT) is catalyzed by 3β -hydroxysteroid 
dehydrogenase/isomerase, which is encoded by two isoenzymes, HSD3B1  and 
HSD3B2 .26  Our unpublished observations suggest that genomic alterations of one or 
both of these genes may contr ibute to the development of resistance to various hormonal 
therapies in prostate cancer.  Genomic DNA will be prepared from collected samples 
(tumor and matched peripheral blood ) using DNeasy Blood and Tissue Kit (QIAGEN, 
________________________________________________________________________  
41 Germantown, MD). PCR products of t he promoter region, all exons, exon -intron junctions 
and the 3’ -UTR will be sequenced to identify mutations in HSD3B1 and HSD3B2 . The 
primers and annealing temperature were described previously.27 To sequence the 3’ 
flanking region of HSD3 B1, primer set (Forward: 5’ -ATGTGGAGGGAGGTGTGAGT -3’ 
and Reverse: 5’ -ACGGAGATGGGTCTCTTCCA -3’) will be used with an annealing 
temperature of 62 C. Genotyping PCR reaction (50 l) consisted of 30 -100 ng genomic 
DNA, 1 x PCR buffer with 0.2 mM dNTP, 0.2 M of each primer, and 0.5 l Phusion High -
Fidelity DNA Polymerase (New England BioLabs Inc, Ipswich, MA).  Tumor and germline 
sequences will be compared in each individual patient to assess for somatically acquired 
mutations.  Samples will be labeled with the su bject’s de -identified study number and 
collection date and delivered for genomic sequence analysis to  
 
Nima Sharifi, M.D.  
Kendrick Family Endowed Chair for Prostate Cancer Research  
Cleveland Clinic  
Lerner Research Institute  
Cancer Biology, NB40  
9500 Eucli d Avenue  
Cleveland, OH 44195  
 
9.3 Specimen Banking  
The tissue used for diagnosis will be stored for 10 years in the CLIA certified clinical 
Pathology laboratory at UTSW. The tissue procured for research will be stored snap 
frozen in the UTSW tissue bank indefi nitely or until used up . Serum and tissue  may be 
used for future additional studies with specific consent from study subjects. If future use 
is denied or withdrawn by the subject, best efforts will be made to stop any additional 
studies and to destroy the specimens.  
 
The specimens, DNA, and their derivatives may have significant therapeutic or 
commercial value . The Informed Consent form contains this information and informs the 
subject that there is the potential for financial gain by UT Southwestern, the investigator , 
and the study sponsors Medivation, Inc . and Astellas Pharma US, Inc.   
 
The following information obtained from the subject's medical record may be provided to 
research collaborators when specimens are made available:  
 Diagnosis  
 Collection time  in relation to study treatment  
 Clinical outcome – if available  
 Demographic data  
10.0 STATISTICAL CONSIDERATIONS  
10.1 Study Design/Study Endpoints  
This is an open -label, single -arm, single -center prospective pilot study of enzalutamide 
plus GnRH agonist treatment co mbined with EBRT in the treatment of men with high -risk 
localized or locally advanced prostate cancer. Select patients with regional lymph node 
involvement (N1 disease) are also eligible to participate in this study.  
 
Primary endpoint:  to determine the sa fety and tolerability of combining enzlutamide plus a 
GnRH agonist with EBRT up to 12 months following initiation of treatment with 
enzalutamide plus GnRH agonist.  
 
Secondary endpoints:  
1. Molecular markers of androgen signaling and cell death in prostate bi opsy samples  
________________________________________________________________________  
42 a. Inhibition of androgen -regulated gene expression (potential  targets to 
include NDRG1, FKBP5, TMPRSS2, and PSA) by qRT -PCR  
b. Inhibition of androgen receptor (AR) nuclear localization and enhancement 
of apoptotic cell death measured by immunohis tochemistry (IHC)  
c. Androgen metabolism in prostate biopsy samples  
2. Serum PSA, testosterone, dehydroepiandrosterone (DHEA), and DHEA -sulfate 
(DHEA -S) following combination therapy with enzalutamide plus GnRH agonist 
therapy prior to initiation of radiation th erapy  
3. Changes in prostate tumor volume and activity following 2 months of combined 
enzalutamide plus GnRH therapy compared to baseline as measured by multi -
parametric magnetic resonance imaging (MRI)  
 
The trial will be halted if unacceptable levels of toxi city are found as defined by 3 or more 
patients withdrawing from the study due to AEs  or if 3 or more patients experience SAEs . 
 
10.2 Sample Size and Accrual  
We propose to enroll ten subjects in this pilot study. The expected accrual rate is 7 
subjects over app roximately 4 months. The primary endpoint is safety and tolerability of 
enzalutamide when combined with GnRH agonist and radiation therapy. Descriptive 
statistics will be computed to assess safety and tolerability. The highest AE score for 
each category ov er the 12 month period following initiation of treatment with 
enzalutamide plus GnRH agonist will be reported for each study subject in the summary 
statistics. Secondary endpoints assess mechanisms of enzalutamide plus GnRH action 
on prostate cancer tissue  and quantitative imaging of localized prostate cancer response 
to enzalutamide plus GnRH therapy. As this is a pilot study, statistical power has not 
been calculated to determine the sample size, and descriptive statistics will be used to 
report outcomes.   
10.3 Data Analyses Plans  
 
Primary endpoint:  to determine the safety and tolerability of combining enzlutamide plus a 
GnRH agonist with EBRT up to 12 months following initiation of treatment with 
enzalutamide plus GnRH agonist. Data analysis plan: descriptive statistics to report the 
number and nature of AEs in all patients over 12 months.  
 
Secondary endpoints:  
1. Molecular markers of androgen signaling and cell death in prostate biopsy samples  
will be analyzed using descriptive statistics  
a. Inhibition of androgen -regulated gene expression (potential  targets to 
include NDRG1, FKBP5, TMPRSS2, and PSA) by qRT -PCR  
b. Inhibition of androgen receptor (AR) nuclear localization and enhancement 
of apoptotic cell death measured by immunohistochemistry (IHC)  
c. Androgen metabolism  in prostate biopsy samples  
2. Serum PSA, testosterone, dehydroepiandrosterone (DHEA), and DHEA -sulfate 
(DHEA -S) following combination therapy with enzalutamide plus GnRH agonist 
therapy prior to initiation of radiation therapy  will be reported using descript ive 
statistics for each patient.  
3. Changes in prostate tumor volume and activity following 2 months of combined 
enzalutamide plus GnRH therapy compared to baseline as measured by multi -
parametric magnetic resonance imaging (MRI)  will be reported using descri ptive 
statistics for each patient and summarized with mean change and standard deviation.  
 
 
________________________________________________________________________  
43 11.0 STUDY MANAGEMENT  
11.1 Conflict of Interest  
 
Any investigator who has a conflict of interest with this study (patent ownership, royalties, 
or financial gain greater than the minimum allowable by their institution, etc.) must have 
the conflict reviewed by  the Conflict of Interest office.  All investigators will follow the  
University conflict of interest policy . 
 11.2 Institutional Review Board (IRB) Approval and Consent  
It is expected that the IRB will have the proper representation and function in accordance 
with federally mandated regulations . The IRB must  approve the consent form and 
protocol.  
 
In obtaining and documenting informed consent, the investigator should comply with the 
applicable regulatory requirement(s), and should adhere to Good Clinical Practice (GCP) 
and to ethical principles that have their origin in the Declaration of Helsinki.  
  
Before recruitment and enrollment onto this study, the subject  will be given  a full 
explanation of the study and will be given the opportunity to review the consent form. 
Each consent form must include all the relevant elements currently required by the FDA 
Regulations and local or state regulations. Once this essential informatio n has been 
provided to the subject  and the investigator is assured that the subject  understands the 
implications of participating in the study, the subject  will be asked to give consent to 
participate in the study by signing an IRB -approved consent form.  
 
Prior to a patient’s participation in the trial, the written informed consent form should be 
signed and personally dated by the subject  and by the person who conducted the 
informed consent discussion.  
11.2 Registration Procedures   
All subjects  must be register ed with the Urology Research Office before enrollmen t to 
study . Prior to registration, eligibility criteria must be confirmed with the (Research Office ) 
Study Coordinator. To register a subject , call 214-645-8787  Monday t hrough Friday, 
9:00AM -5:00PM.  
11.3 Data  Management and Monitoring  
The UTSW Simmons Cancer Center (SCC) Data Safety Monitoring Committee (DSMC) 
is responsible for monitoring data quality and patient safety for all UTSW SCC clinical 
trials.  As part of that responsibility, the DSMC reviews all lo cal serious adverse events in 
real time as they are reported and reviews adverse events on a quarterly basis.  The 
quality assurance activity for the Clinical Research Office provides for periodic auditing of 
clinical research documents to ensure data inte grity and regulatory compliance.  
  
The SCC DSMC meets quarterly and conducts annual comprehensive reviews of 
ongoing clinical trials, for which it serves as the DSMC of record.  
11.4 Adherence to the Protocol  
Except for an emergency situation in which proper ca re for the protection, safety, and 
well-being of the study subject  requires alternative treatment, the study shall be 
conducted exactly as described in the approved protocol .  
________________________________________________________________________  
44 11.4.1  Emergency Modifications  
Investigators may implement a deviation from, or a chang e of, the protocol to 
eliminate an immediate hazard(s) to trial subjects without prior IRB approval .  
 
For any such emergency modification implemented, an IRB modification form 
must be completed within  five (5) business days of making the change . 
11.4.2  Other Pro tocol Deviations/Violations  
All other planned deviations from the protocol must have prior approval by the  
Principal Investigator and the IRB . According to the IRB, a protocol deviation  is 
any unplanned variance from an IRB approved protocol that:  
 Is gene rally noted or recognized after it occurs  
 Has no substantive effect on the risks to research participants  
 Has no substantive effect on the scientific integrity of the research plan or the 
value of the data collected  
 Did not result from willful or knowing misconduct on the part of the 
investigator(s).  
 
An unplanned protocol variance is considered a violation  if the variance:  
 Has harmed or increased the risk of harm to one or more research 
participants.  
 Has damaged the scientific integrity of the data colle cted for the study.  
 Results from willful or knowing misconduct on the part of the investigator(s).  
 Demonstrates serious or continuing noncompliance with federal regulations, 
State laws, or University policies.  
 
11.5 Amendments to the Protocol  
Should amendments to the protocol be required, the amendments will be originated and 
documented by t he Principal Investigator .  When an amendment to the protocol 
substantially alters the study design or the potential risk to the patient, a revised consent 
form might be requ ired.  
 
The written amendment, and if required the amended consent form, must be sent to the 
IRB for approval prior to implementation .  
11.6 Record Retention  
Study documentation includes all Case Report Forms, data correction forms or queries, 
source documents,  Sponsor -Investigator correspondence, monitoring logs/letters, and 
regulatory documents (e.g., protocol and amendments, IRB correspondence and 
approval, signed patient consent forms).  
 
Source documents include all recordings of observations or notations of  clinical activities 
and all reports and records necessary for the evaluation and reconstruction of the clinical 
research study.  
 
Government agency regulations and directives require that the study investigator retain 
all study documentation pertaining to the conduct of a clinical trial . In the case of a study 
with a drug seeking regulatory approval and marketing, these documents shall be 
retained for at least two years after the last approval of marketing application in an 
International Conference on Harmo nization (ICH) region . In all other cases, study 
documents should be kept on file until three years after the completion and final study 
report of this investigational study.  
________________________________________________________________________  
45 11.7 Obligations of Investigators  
The Principal Investigator is responsible for the co nduct of the clinical trial at the site in 
accordance with Title 21 of the Code of Federal Regulations and/or the Declaration of 
Helsinki . The Principal Investigator is responsible for personally overseeing the treatment 
of all study patients . The Principa l Investigator must assure that all study site personnel, 
including sub -investigators and other study staff members, adhere to the study protocol 
and all FDA/GCP/NCI regulations and guidelines regarding clinical trials both during and 
after study completio n. 
 
The Principal Investigator at each institution or site will be responsible for assuring that all 
the required data will be collected and entered onto the Case Report Forms. Periodically, 
monitoring visits may be conducted and the Principal Investigator  will provide access to 
his/her original records to permit verification of proper entry of data. At the completion of 
the study, all case report forms will be reviewed by the Principal Investigator and will 
require his/her final signature to verify the acc uracy of the data.  
12.0 REFERENCES  
 
1. Bolla M, Collette L, Blank L, et al. Long -term results with immediate androgen 
suppression and external irradiation in patients with locally advanced prostate cancer (an 
EORTC study): a phase III random ised trial. Lancet 2002;360:103 -6. 
2. Bolla M, de Reijke TM, Van Tienhoven G, et al. Duration of androgen suppression in the 
treatment of prostate cancer. The New England journal of medicine 2009;360:2516 -27. 
3. Bolla M, Van Tienhoven G, Warde P, et al. Ex ternal irradiation with or without long -
term androgen suppression for prostate cancer with high metastatic risk: 10 -year results of an 
EORTC randomised study. The lancet oncology 2010;11:1066 -73. 
4. D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Androgen suppression 
and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA : the journal of the 
American Medical Association 2008;299:289 -95. 
5. Horwitz EM, Bae K, Hanks GE, et al. Ten -year follow -up of radiation therapy oncology 
group protocol 92 -02: a phase III trial of the duration of elective androgen deprivation in locally 
advanced prostate cancer. Journal of clinical oncology : official journal of the American Society 
of Clinical Oncology 2008;26:2497 -504. 
6. Pilepich MV, Wint er K, Lawton CA, et al. Androgen suppression adjuvant to definitive 
radiotherapy in prostate carcinoma --long-term results of phase III RTOG 85 -31. International 
journal of radiation oncology, biology, physics 2005;61:1285 -90. 
7. Souhami L, Bae K, Pilepich M, Sandler H. Impact of the duration of adjuvant hormonal 
therapy in patients with locally advanced prostate cancer treated with radiotherapy: a secondary 
analysis of RTOG 85 -31. Journal of clinical oncology : official journal of the American Society 
of Cl inical Oncology 2009;27:2137 -43. 
8. Warde P, Mason M, Ding K, et al. Combined androgen deprivation therapy and radiation 
therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet 2011;378:2104 -
11. 
9. Widmark A, Klepp O, Solberg A, e t al. Endocrine treatment, with or without 
radiotherapy, in locally advanced prostate cancer (SPCG -7/SFUO -3): an open randomised phase 
III trial. Lancet 2009;373:301 -8. 
10. Scher HI, Beer TM, Higano CS, et al. Antitumour activity of MDV3100 in castration -
resistant prostate cancer: a phase 1 -2 study. Lancet 2010;375:1437 -46. 
________________________________________________________________________  
46 11. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer 
after chemotherapy. The New England journal of medicine 2012;367:1187 -97. 
12. Society AC. C ancer Facts & Figures 2012. In. Atlanta: American Cancer Society; 2012.  
13. Jung ME, Ouk S, Yoo D, et al. Structure -activity relationship for thiohydantoin androgen 
receptor antagonists for castration -resistant prostate cancer (CRPC). J Med Chem 2010;53:27 79-
96. 
14. Tran C, Ouk S, Clegg NJ, et al. Development of a second -generation antiandrogen for 
treatment of advanced prostate cancer. Science 2009;324:787 -90. 
15. Qayyum A, Coakley FV, Lu Y, et al. Organ -confined prostate cancer: effect of prior 
transrecta l biopsy on endorectal MRI and MR spectroscopic imaging. AJR Am J Roentgenol 
2004;183:1079 -83. 
16. Bloch BN, Lenkinski RE, Rofsky NM. The role of magnetic resonance imaging (MRI) in 
prostate cancer imaging and staging at 1.5 and 3 Tesla: the Beth Israel De aconess Medical 
Center (BIDMC) approach. Cancer Biomark 2008;4:251 -62. 
17. Wang Y, Alkasab TK, Narin O, et al. Incidence of nephrogenic systemic fibrosis after 
adoption of restrictive gadolinium -based contrast agent guidelines. Radiology 2011;260:105 -11. 
18. Barentsz JO, Richenberg J, Clements R, et al. ESUR prostate MR guidelines 2012. Eur 
Radiol 2012;22:746 -57. 
19. Hara N, Okuizumi M, Koike H, Kawaguchi M, Bilim V. Dynamic contrast -enhanced 
magnetic resonance imaging (DCE -MRI) is a useful modality for the  precise detection and 
staging of early prostate cancer. Prostate 2005;62:140 -7. 
20. Ukimura O, Hung AJ, Gill IS. Innovations in prostate biopsy strategies for active 
surveillance and focal therapy. Curr Opin Urol 2011;21:115 -20. 
21. Villers A, Puech P, Mo uton D, Leroy X, Ballereau C, Lemaitre L. Dynamic contrast 
enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for 
predicting tumor volume: correlation with radical prostatectomy findings. J Urol 2006;176:2432 -
7. 
22. Tamad a T, Sone T, Jo Y, et al. Apparent diffusion coefficient values in peripheral and 
transition zones of the prostate: comparison between normal and malignant prostatic tissues and 
correlation with histologic grade. J Magn Reson Imaging 2008;28:720 -6. 
23. Woo dfield CA, Tung GA, Grand DJ, Pezzullo JA, Machan JT, Renzulli JF, 2nd. 
Diffusion -weighted MRI of peripheral zone prostate cancer: comparison of tumor apparent 
diffusion coefficient with Gleason score and percentage of tumor on core biopsy. AJR Am J 
Roentg enol 2010;194:W316 -22. 
24. Mendiratta P, Mostaghel E, Guinney J, et al. Genomic strategy for targeting therapy in 
castration -resistant prostate cancer. J Clin Oncol 2009;27:2022 -9. 
25. Evaul K, Li R, Papari -Zareei M, Auchus RJ, Sharifi N. 3beta -hydroxyster oid 
dehydrogenase is a possible pharmacological target in the treatment of castration -resistant 
prostate cancer. Endocrinology 2010;151:3514 -20. 
26. Chang KH, Sharifi N. Prostate cancer -from steroid transformations to clinical translation. 
Nat Rev Urol 201 2;9:721 -4. 
27. Chang BL, Zheng SL, Hawkins GA, et al. Joint effect of HSD3B1 and HSD3B2 genes is 
associated with hereditary and sporadic prostate cancer susceptibility. Cancer Res 2002;62:1784 -
9. 
 
 
 
________________________________________________________________________  
47  